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ABSTRACT 
TARGETED DELIVERY OF EMBELIN TO CANCER CELL 
Z. Emjedi 
MSc thesis, Department of Biotechnology, Faculty of Natural Science, University of the 
Western Cape, South Africa. 
Apoptosis or programmed cell death is vital to the development of organisms as they 
maintain the balance between cell death and cell growth. Failure to activate apoptosis has 
been implicated in carcinogenesis and often results from the over expression of anti–cancer 
proteins such as the X–linked inhibitor of apoptosis protein (XIAP). XIAP is over expresses 
in certain cancers and is a potent inhibitor of the initiator caspase 9 and effector caspases 3 
and 7. The increased expression of XIAP in cancer cells result in the resistance to apoptosis. 
The control of XIAP is therefore considered as a target for anti–cancer drug development. 
Embelin or 2,5–dihydroxy–3–undecyl–1,4–benzoquinoine is a dihydroxyquinone compound 
that was previously shown to inhibit XIAP. This drug was discovered by structure based 
computational screening. The binding of embelin to XIAP displaces XIAP from caspases, 
consequently eliminating the inhibitory effect of XIAP on apoptosis. 
The objective of this study was to develop a gold nanoparticle that can be used for the 
targeted delivery of embelin to cancer cells thereby enhancing pro–apoptotic effects of the 
pro–apoptotic drug, ceramide. XIAP expression levels were investigated by Western blot 
analysis in a panel of human cancer cell lines available in the laboratory to identify two cell 
lines that can be used as low and high XIAP expression controls. Gold nanoparticles were 
synthesized and conjugated with embelin and a cancer targeting peptide with the amino acid 
sequence LTVSPWY. The biconjugated nanoparticles were used to co–treat MCF7 and 
HepG2 cells with ceramide. Apoptosis was quantified using flow cytometry. The uptake of 
gold nanoparticles was investigated using HR–TEM and ICP–OES. This study showed that 
gold nanoparticles conjugated with the LTVSPWY peptide is specifically targeted to and 
taken up by cancer cells. Gold nanoparticles conjugated with embelin promoted ceramide 
induced apoptotic cell death of cancer cells. However, it was observed that gold nanoparticles 
biconjugated with the LTVSPWY peptide and embelin failed to enhance the pro–apoptotic 
effects of ceramide.  
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This study successfully demonstrated that gold nanoparticles conjugated with embelin could 
be used to enhance the effects of anti–cancer drugs using ceramide as an example. 
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1.1.Cancer and associated risk factors 
1.1.1. Cancer development 
Cancer is a group of diseases which are characterized by the uncontrolled growth of cells 
with abnormal DNA. When a cell detects DNA damage, it triggers its DNA repair 
mechanism. Failure of the cell to repair DNA damage results in the instability in its genome. 
Under normal conditions, apoptosis is triggered to ensure that the damaged cells do not 
survive and multiply. In the event where these cells are not destroyed by apoptosis cancer can 
develop (Figure 1.1) (Gotter, 2009). Cancer arises from various factors including inherited 
mutations, immune disorders, hormone imbalances, tobacco, chemicals, as well as radiation 
(Cretney et al., 2007). Cancer cell proliferation arises as a result of the interaction between 
the DNA damaged cell and the non–damaged cell. As a result of the interaction, practically 
all types of human tumours, especially their metastatic outgrowths, continue to spread the 
defects to various cell types resulting in the formation of malignant growth (Hanahan and 
Weinberg, 2000). 
 
Figure 1.1: Pathway leading to cancer following DNA damage. When the DNA of a 
cell is damaged, signalling cascades are triggered to repair the damaged DNA. If DNA 
repair in unsuccessful, the genome becomes unstable which, under normal conditions, 
trigger apoptosis. Should the events leading to apoptosis are terminated the result will be 
the development of cancer (Gotter, 2009). 
According to Ferlay and colleagues more than 85% of the “global cancer burden”, for liver 
cancer, occurs in developing countries. Regions regarded as being high risk for liver cancer, 
are Eastern and Western Africa, Southern Africa, South Central Asia, Central Africa and 
Southern America where the cumulative risk of developing cancer range from 3.8 (highest) to 
2.5 (lowest). Regions regarded as being low risk are Western Asia, North America and 
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Australia/New Zealand where the risk of developing cancer was constant at 0.5% (Ferley et 
al., 2010). 
1.1.2. Global statistics for breast and liver cancer cells 
According to Ferlay and colleagues, the 2008 statistics shows that lung cancer remains the 
most common cancer in the world as it has a number 1.6 million cases which accounts for 
12.7% of all cancers and with a death toll of 1.4 million (18.2% of all deaths). The second 
most common cancer overall is breast cancer. It has 1.4 million cases (10.9%) but is the fifth 
highest cause of death (458 000 deaths, 6.1%). Regarding the incidence of cancer, colorectal 
cancer has been reported to be responsible for 608 000 deaths, stomach cancer 738 000 
deaths, prostate cancer 261 000 deaths and liver cancer 695 000 deaths (Ferlay et al., 2010). 
The global cancer statistics of 2008 supports statistics the study conducted by Parton and 
colleagues where breast cancer was identified as the most common and frequent malignancy 
among women (Parton et al., 2001; Ferley et al., 2010). Parton and colleagues identified 
breast cancer to comprise 18% of all cancers in women (Parton et al., 2001) where one in 
eight women will develop breast cancer in their lifetime (Johnson and Guthrie, 2000). For the 
purpose of this study, focus will be on breast and liver cancer. 
During 2008 approximately 1.38 million new breast cancer cases were diagnosed. Therefore 
with an overall global percentage incidence of 10.9% breast cancer ranks second when 
comparing all cancers. With an estimate of 690 000 new cases of breast cancer in both 
developed and developing countries, breast cancer is emerging as the most common cancer in 
a population ratio of 1:4 for developed and developing countries respectively. As a results of 
458 000 deaths due to breast cancer, when compared to other cancer related deaths breast 
cancer ranks fifth. However it must be noted that breast cancer is the most frequent cause of 
death among women in developing countries where accounting for 269 000 deaths or a total 
percentage of 12.7% within developing regions alone (Ferlay et al., 2010). 
According to the global statistics, liver cancer is the fifth most common cancer in men and 
seventh most common in women. It is the third most common cause of cancer related deaths 
worldwide. Most of the liver cancer cases diagnosed have been reported in developing 
countries where regions of high incidence are Eastern and South–Eastern Asia, Central and 
Western Africa, Melanesia and Micronesia–Polynesia (Ferlay et al., 2010).  
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1.1.3. Impact of genetics and lifestyle on cancer development 
The risk of developing breast cancer depends on a number of factors. While age and gender 
are the two pre–dominant cancer risk factors (Carter and Church, 2009), Trentham–Dietz and 
colleagues suggested that a family history in the case of breast cancer as well as potentially 
modifiable characteristics such as body weight, alcohol consumption and post–menopausal 
hormone use may be associated with a secondary risk of developing breast cancer 
(Trentham–Dietz et al., 2007). The link between cancer and socio–economic conditions 
suggest that lifestyle may also impact on the risk of developing cancer. Together with pre–
existing risk factors may it bring about a change in the incidence of cancer, especially in the 
developing countries with regard to the use of tobacco, alcohol consumption, nutritional 
habits as well as physical activity (Ferley et al., 2010). 
 
1.2.Apoptosis 
1.2.1. Apoptotic cell death 
According to Fry and Vassiley the development and progression of cancer is associated with 
irregularities in biochemical pathways (Fry and Vassiley, 2005). One of the biochemical 
pathways that are often affected in cancer cells is the apoptotic pathways. 
Programmed cell death or apoptosis are descriptive definitions of a specific form of cell death 
(Kroemer et al., 2005) which have been implicated in a variety of both physiological and 
pathological process (Green and Martin, 1995). 
Apoptosis is a multi–stage process characterized by cell shrinkage, chromatin condensation 
as well as nuclear and cell fragmentation. The final stage of apoptosis is characterized by the 
formation of apoptotic bodies (Figure 1.2) which are engulfed by neighbouring phagocytic 
cells (Gewies, 2003; Gotter, 2009). 
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Figure 1.2: Process of apoptotic cell death. Apoptotic cells differ from viable cells in 
that apoptotic cells shrink upon deformation caused by chromatic condensation and 
nuclear cell fragmentation, which is followed by the plasma membrane “budding” 
resulting in cell fragmentation and finally the formation of membrane enclosed 
structures known as apoptotic bodies [adapted from Gewies, 2003]. 
This fast and effective form of cell death is an ordered set of events responsible for cell death 
during the development of multicellular organisms (Blagosklonny, 2004) and thereby control 
the development of the organism (Fisher and Schulze–Osthoff, 20051; Gotter, 2009). 
Apoptosis is essential in the development of the immune system (Fisher and Schulze–Osthoff 
2005
2
). Apoptosis controls the cell number (Gotter, 2009) as it maintains the balance between 
cell death and cell proliferation (Fisher and Osthoff, 2005
2
). Apoptosis has become a key 
interest in biomedical research as it plays a central role in physiological processes such as 
morphogenesis, negative selection in the immune system as well as cancer surveillance 
(Hengartner, 1996). 
1.2.2. Apoptosis pathways 
Apoptosis induction may be achieved by the increased expression of pro–apoptotic factors 
whilst reducing the expression of anti–apoptotic factors (Ghavami et al., 2009). As 
deregulation of apoptosis is implicated in a number of diseases, apoptosis is seen as a target 
for the development of alternative therapeutic strategies (Fisher and Schulze–Osthoff, 20051). 
Apoptosis is executed via two distinct signalling pathways, namely the intrinsic or the 
mitochondrial pathway and the extrinsic or death receptor pathway (Figure 1.3) (Fisher and 
Schulze–Osthoff, 20052). A third pathway, known as the granzyme B pathway also exist 
(Salvesen and Dixit, 1997; Thornberry and Lazebnik, 1998). 
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Figure 1.3: The two major apoptotic pathways. The extrinsic (or death receptor 
pathway) and the intrinsic (or mitochondrial) pathways leading to apoptosis appear on the 
left and ight, respectively. It must be noted that the extrinsic and intrinsic pathway both 
converge at the stage of caspase activation which activates the same downstream caspases 
resulting in apoptotic cell death (Fisher and Schulze–Osthoff, 20052). 
The extrinsic pathway is initiated by the ligation of death receptors such as Fas/CD95, TNF 
receptor and/or TRAIL receptor. Death receptors function in activating initiator caspases 8 
and 10 which, in turn, directly activates effector caspases 3 and 7 (Nachmais et al., 2004; 
Salvesen and Dixit, 1997; Thornberry and Lazebnik, 1998; Raychaundhuri, 2010). 
The intrinsic pathway is initiated in response to intracellular stresses such as DNA damage, 
hypoxia and/or growth factor deprivation (Sousa and Espreafico, 2006). The caspase cascade 
is triggered by an increase in the permeability of the mitochondrial membrane and the release 
of cytochrome c. These mitochondrial changes result in the formation of apoptosomes 
consisting of pro–caspase 9, Apaf–1, cytochrome c and dATP. The formation of the 
apoptosome results in caspase 9 activation, which in turn activates caspase 3 (Salvesen and 
Dixit, 1997; Thornberry and Lazebnik, 1998; Nachmias et al., 2004). Caspase 3 cleaves 
and/or degrade cellular substrates (Fisher and Schulze–Osthoff, 20052; Friedrich et al., 2001) 
thereby inactivating enzymes or disassembling cellular structures (Friedrich et al., 2001). 
 
 
 
 
6 
 
1.2.3. Ceramide as an inducer of apoptosis 
Apoptosis can be triggered either by activating the extrinsic pathway by the presence of death 
receptors. Alternatively, the intrinsic or mitochondrial pathway may also be activated in 
response to DNA damage. Apoptosis may also be triggered in vitro using anti–tumour agents. 
Some examples of anti–tumour agents used in human cancer models are doxorubicin, 
paclitaxel, daunorubicin, and ceramide (Monrad and Cabot, 2013). 
Ceramide, a product resulting from sphingolipid metabolism, consist of N–acetylated (14 to 
16 carbons) sphingosine (18 carbons). It is comprised of hydroxyl groups situated at carbons 
1 and 3, a trans double bond between carbons 4 and 5 which is important for its biological 
activity as well as an amino group positioned at carbon 2 (Figure 1.4) (Pettus, 2002; 
Ogretmen and Hannun, 2004). 
 
Figure 1.4: Structure of ceramide. Ceramide is comprised of sphingosine and a fatty acid. 
An important feature to note is the trans double bond present between carbons 4 and 5 (Radin, 
2003). 
Sphingomyelin is the main lipid in the plasma membrane of mammalian cells. Hydrolysis of 
sphingomyelin is the major source of ceramide (Hannun, 1996; Herr and Debatin, 2001). In 
vivo ceramide generation may be achieved through multiple pathways. The de novo and 
sphingomyelin pathways are mainly involved in increasing exogenous ceramide levels 
(Figure 1.5) (Hannun, 1996; Ogtretmen and Hannun, 2004). 
1.2.3.1.Ceramide generation 
Ceramide generation via the de novo pathway is as a result of serine and palmitoyl–CoA 
reacting with serine palmitoyl transferase to generate 3–ketosphinganine (Figure 1.5). The 
resulting shinganine is converted to dihydroceramide due to the action of fatty acyl coenzyme 
A and dihydroceramide kinase. Ceramide results from the action of dihydroceramide 
desaturase on dihydroceramide (Ogretman and Hannun, 2004). Ceramide generation also 
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involves the activation of the enzyme spingomyelinase or SMase (Hannun, 1996; Jiang et al., 
2000, Ogretman and Hannun, 2004) in response to TNF and other cytokines (Hannun, 1996). 
Upon SMase activation sphingomyelin is cleaved thereby releasing phophocholine and 
ceramide (Andrieu–Abadie et al., 2001). 
 
Figure 1.5: Pathways of ceramide generation. A major source of ceramide generation occurs via 
sphingomyelin hydrolysis. In vivo ceramide generation is generated by the de novo pathway [adapted from 
(Ogretman and Hannun, 2004)]. 
1.2.3.2.Effects of ceramide and ceramide analogues treatments 
C2– and C6– ceramide are short chain analogues of ceramide. These two short chain 
ceramides mimic some of the signalling events of endogenous ceramide. It must be noted that 
endogenous ceramide is a hydrophobic molecule whereas the short chain ceramides are water 
soluble molecules. Therefore, it is unlikely that these short chain ceramides carries out all the 
biological functions of endogenous ceramide (Wagenknecht et al., 2001). 
Initiators of apoptosis such as TNF, daunorubicin, γ and ultraviolet (UV) radiation as well as 
growth factor removal are associated with an increase in the production of ceramide (Jiang et 
al., 2000). Intracellular levels of ceramide increase in response to many chemotherapy drugs, 
 
 
 
 
8 
 
ionizing radiation as well as cytokines. These responses induce morphological changes in the 
cells which are indicative of apoptotosis (Shabbits et al., 2003). 
According to Radin apoptosis almost always occurs when cancer cells are treated in vitro 
with exogenous ceramide (Radin, 2003). According to Hannun and Luberto apoptosis among 
most cancer cells triggered by ceramide may be accompanied by cell cycle arrest (Hannun 
and Luberto, 2000). 
Treatment with exogenous ceramide analogues enables ceramide to mimic the role of 
apoptosis inducers via direct molecular interactions. In these cases, ceramide exerts its killing 
effect on specific targeting molecules thereby activating subsequent signalling cascades 
(Shabbits et al., 2001). In an experiment carried out by Jiang and colleagues, HeLa cells were 
treated the 50 µM C2–ceramide and no obvious morphological changes were observed within 
the first three hours. However, after six hours crevices appeared between the cells where 
some of the cells resembled a rounded shape. It was also reported that many reflective 
organelles that were not visible in the untreated cells were visible in the treated cells. Within 
24 hours more than 90% of HeLa cells were detached whilst the untreated HeLa cells grew 
into a compact monolayer. To confirm that the morphological changes in HeLa cells treated 
with ceramide was due to apoptosis, cells were fixed with glutaraldehyde and examined 
under a transmission electron microscope (Jiang et al., 2000). Therefore apoptosis results due 
to the relationship between ceramide production and subsequent cell death (Jiang et al., 
2000).  
1.2.4. Defective pathways 
Incorrect or inaccurate regulation of apoptosis may result in pathological conditions. Acute 
pathologies such as stroke, heart attack or liver failure are associated with the sudden death of 
tissues within organs through the activation of apoptosis (Fisher and Schulze–Osthof, 20052). 
When comparing pathological conditions to neurodegenerative syndromes, some syndromes 
results from the slow progression of neuronal cell death. Inappropriate low apoptotic rates 
may promote survival and accumulation of abnormal cells which may result in tumour 
formation or autoimmune diseases. Therefore it may be summarized that too little or too 
much cell death may contribute to medical illnesses (Fisher and Schulze–Osthoff, 20052). 
Both the development and the unimpaired state of multicellular organisms are affected by the 
inactivation of apoptosis. Besides developmental abnormalities, defective or inactive 
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apoptosis pathways may lead to tumourigenesis, autoimmune diseases and other serious 
health problems. Defective apoptosis pathways may also be the leading cause of 
chemoresistance in cancer therapy (Ghavami et al., 2009). A common feature of cancer cells 
is their ability to evade apoptosis as a result of alterations that block cell death signalling 
pathways (Meng et al., 2006). The inactivation of apoptosis pathways is central to the 
development of cancer. The disabling of apoptotic responses may be a major contributor both 
to resistance to treatment and to the observation that, in many tumours, apoptosis is not the 
main mechanism for the death of cancer cells in response to common treatment regimens 
(Brown and Attardi, 2005). 
 
1.3.Relations between Inhibitor of Apoptosis Proteins and cancer 
The X–linked inhibitor of apoptosis protein (XIAP) is a protein that has been shown to be 
over expressed in malignant cancers progression (Tamm et al., 2000; Liu et al., 2011). XIAP 
has been reported to inhibit both the intrinsic or mitochondrial and extrinsic or death receptor 
pathways by inhibiting caspase activity. 
According to LaCasse and colleagues evidence exist for the involvement of inhibitor of 
apoptosis proteins (IAPs) in cancer. They reported the cancer specific expression of the IAP 
Survivin which is not normally expressed in differentiated tissue and the anti–apoptotic 
effects of IAPs are mediated via the NF–κB transcription factor (LaCasse et al., 1998). 
1.3.1. Inhibitor of apoptosis proteins 
IAP family members are defined by one or more repeats of a highly conserved region 
approximately 70 amino acids long, termed the baculovirus IAP repeat or BIR domain 
(Deveraux et al., 1999; Nachmias et al., 2003) located at the amino terminus (Nachmias et 
al., 2003) and consists of cysteine and histidine residues within their core sequence 
CX2CX6WX3DX5HX6C where X can be any amino acid (Deveraux and Reed, 1999; Holcik et 
al., 2001). The following eight human IAPs have been identified: c–IAP1, c–IAP2, NAIP, 
Survivin, XIAP, Bruce, ILP–2 and Livin. With the exception of NAIP and Survivin, human 
IAPs also contain a conserved sequence known as the RING finger located at the carboxyl 
terminus (Nachmias et al., 2003). 
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IAPs are a family of anti–apoptotic proteins. Their main function is to regulate caspase 
activity. IAPs regulate apoptosis by inhibiting caspase 3 and /or caspase 7. IAPs also prevent 
the initiation of the intrinsic pathway by directly inhibiting caspase 9 (Riedl et al., 2001). 
IAPs have been shown to protect cells against apoptosis induced by the Fas ligand, TNFα, 
transducers of the TNF receptor super–family namely RIP, RIP2/RICK/CARDIAK, FADD 
and v–Rel, Bcl–2 pro–apoptotic family members, chemotherapeutic drugs such as etoposide, 
cisplatin, taxol, actinomycin D and adramycin, ionizing or UV radiation, oxidative stress, 
ischemia, potassium withdrawal, growth factor withdrawal, caspases, and Drosophila death 
receptors (LaCasse et al., 1998). 
1.3.2. X–chromosome linked inhibitor of apoptosis protein (XIAP) and its relation to 
cancer 
Among the human IAPs, X–chromosome linked inhibitor of apoptosis protein (XIAP) is the 
best and most thoroughly characterized (Holcik et al., 2003; Fischer and Schulze–Osthoff, 
2005
2
). It was shown that XIAP over expression protects cancerous cells from apoptotic 
triggers induced by UV–irradiation, γ–irradiation as well as chemotherapeutic drugs. The 
ability to adjust XIAP activity via a subset of cellular proteins would be essential for 
maintaining control of apoptosis. But, if XIAP is left unchecked, it may lead to cancer 
(Holcik et al., 2003). 
XIAP is comprised of three BIR domain regions as well as a RING domain (Figure 1.6) 
(Holcik et al., 2003; Schimmer, 2004) and it was the first IAP to be characterized (Schimmer, 
2004). 
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Figure 1.6: Functional domains of the XIAP protein. XIAP is comprised of three BIR 
domains as well as a RING domain. BIR regions 1 and 2 inhibit the intrinsic or mitochondrial 
pathway, of apoptosis, by blocking caspases 3 and 7. The extrinsic apoptotic pathway is 
inhibited by capase 3 and the RING domain blocking caspase 9 [adapted from (Holcik et al., 
2001)]. 
In an experiment carried out by Tamm and colleagues, it was observed that XIAP was widely 
expressed in the NCI panel of 60 human tumour cell lines. It was noted that XIAP and c–
IAP1 were widely expressed among tumour cell lines (Tamm et al., 2000). The expression of 
XIAP prevents the activation of caspases, and hence blocks the activation of apoptosis by 
anti–cancer drugs. Inhibition of XIAP binding to caspases may help restore sensitivity to 
apoptosis and thus promote the action of anti–cancer drugs.  
 
1.4.Embelin: an inhibitor of XIAP 
1.4.1. Structure of embelin 
The fruit of the plant Embelia ribes, from the Myrsinaceae family (Pathan and Bhandari, 
2011), has been used for thousands of years in the treatment of fever and inflammation. The 
bio active component isolated from this plant is embelin (Siegelin et al., 2009) or 2,5–
dihydroxy–3–undecyl–1,4–benzoquinone (Joshi et al., 2007; Pathan and Bhandari, 2011). 
Embelin consist of a dihydroxyquinone core and an 11–carbon alkyl side chain (Schimmer et 
al., 2006) (Figure 1.7) which possesses hydrophobic characteristics (Chen et al., 2006).  
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Figure 1.7: Chemical structure of embelin. Embelin consists of a quinone core to which 
a hydrophobic chain is attached (Nikolovska–Coleska et al., 20042). 
Many naturally occurring anti–cancer substances are quinone containing compounds. Some 
examples of these anti–cancer drugs include Adramycin, daunorubicin, mitomycin C, 
streptonigrin, and lapachol (Bachur et al., 1978). 
Quinone is a general term used to classify ubiquitous class of compounds common in many 
natural products and endogenous biochemicals. Quinones are highly redox active molecules 
which can redox cycle resulting in the formation of reactive oxygen species (ROS) which has 
been reported to be associated with cancer (Schumacker, 2006). Quinones may be generated 
via the metabolism of hydroquinones and/or catechols. Quinones are named as derivatives of 
their parent aromatic systems. An example would be benzoquinones derived from benzene 
(Bolton et al., 2000). 
1.4.2. Embelin as an inhibitor of XIAP 
Embelin possess anti–tumour as well as anti–inflammatory properties (Joshi et al., 2007; 
Siegelin et al., 2009). Embelin is a fairly potent, non–peptidic, cell–permeable, small 
molecule inhibitor of the anti–apoptotic protein XIAP. It was identified by computational 
screening of a traditional herbal medicine three–dimensional structure database, consisting of 
82221 natural herbal products (Nikolovska–Coleska et al., 20041; Nikolovska–Coleska et al., 
2004
2
). 
According to Ahn and colleagues embelin not only functions in inhibiting XIAP but also in 
inhibiting NF–κB which is a transcription factor that regulates the expression of anti–
apoptotic proteins such as Bcl-xl (Ahn et al., 2007). 
Ziedan and colleagues reported that embelin can induce apoptosis in two ways. Firstly 
embelin was shown to selectively inhibit cell growth in prostate cancer cells. Secondly 
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embelin was also shown to activate caspase 9 effectively (Ziedan et al., 2008). Xu and 
colleagues conducted a study investigating the anti–proliferative activity of 5–O–
ethylembelin and 5–O–methylembelin in HeLa and HL–60 cells. Both these cell lines were 
treated with 5–O–ethylembelin and 5–O–methylembelin to a final concentration of 10 µM for 
48 hours. A decrease in cell viability was observed, post 48 hour treatment (Xu et al., 2005).  
 
1.5.  Embelin targets XIAP via its BIR3 domain 
1.5.1. Relation between XIAP’s BIR3 and Smac/DIABLO 
Several proteins are released from the mitochondrial intermembrane space into the cytoplasm 
in response to apoptotic stimuli. These proteins include cytochrome c, second mitochondria–
derived activator (Smac/DIABLO), apoptosis inducing factor (AIF), endonuclease G and 
Omi/HtrA2 (Shiozaki and Shi, 2004). 
Smac/DIABLO binds to IAPs and interferes with the ability of IAPs, and more specifically 
XIAP, to block the activation of caspases 3, 7, and 9 (Hao and Mak, 2010; Riedl et al., 2001; 
Fesik, 2005). This interference antagonizes the anti–apoptotic activity thereby promoting 
apoptosis (Riedl et al., 2001; Fesik, 2005). Generally, XIAP inhibition has been thought to 
facilitate apoptosis (Hao and Mak, 2010). XIAP is neutralized by Smac/DIABLO upon 
inhibition of caspase 9 as there is competition for the same specific binding site of XIAP with 
caspase 9 (Gao et al., 2007).  
According to Nikolovska–Coleska and colleagues as well as Schimmer and colleagues 
embelin binds to XIAP’s BIR3 domain with an affinity similar to that of Smac/DIABLO 
(Nikolovska–Coleska et al., 20042; Schimmer et al., 2006). Schimmer and colleagues go a 
step further in that they specify that embelin’s alkyl side chain binds to the surface groove of 
XIAP’s BIR3 domain (Schimmer et al., 2006). 
Liu and colleagues carried out an experiment where they determined the solution structure of 
XIAP’s BIR3 domain using a peptide, comprised of 9 residues, derived from 
Smac/DIABLO’s N terminus in order to understand the structural basis for molecular 
recognition between Smac/DIABLO and IAPs. From their results, they made the following 
observations: (i) the Smac/DIABLO protein binds to XIAP’s BIR3 domain with the same 
affinity as Smac/DIABLO peptides, (ii) both Smac/DIABLO proteins and peptides bind more 
 
 
 
 
14 
 
tightly to XIAP’s BIR3 domain than XIAP’s BIR2 domain, (iii) XIAP’s BIR3–
Smac/DIABLO peptide complex, as determined by NMR, indicated that residues 258 – 346 
of XIAP’s BIR3 domain fits Smac/DIABLO peptide residues 1’ – 4’ best (Figure 1.8), (iv) 
XIAP’s BIR3–Smac/DIABLO peptide complex was comprised of three stranded β–sheets, 
five α–helices (Figure 1.8), one turn of a 310 helix as well as a zinc atom that was chelated to 
three cysteines and a histidine and (v) the ability of mutant proteins to bind to the 
Smac/DIABLO peptide matched their ability to inhibit caspase 9 which suggests that 
Smac/DIABLO and caspase 9 bind overlapping sites on XIAP’s BIR3 domain. This enables 
Smac/DIABLO to free caspase 9 from the XIAP/caspase 9 complex in order to fulfil its role 
in the apoptotic pathway. It must be noted that the binding sites for Smac/DIABLO and 
caspase 9 are not identical. Liu and colleagues were able to conclude that Smac/DIABLO 
interacts with IAPs in the same manner as shown by XIAP’s BIR3–Smac/DIABLO peptide 
complex. This was confirmed by primary sequence alignments. Three–dimensional structures 
in the region of XIAP’s BIR3 domain and of other structurally characterized IAPs that bind 
to Smac/DIABLO are also similar (Liu et al., 2000). 
 
Figure 1.8: NMR structure of XIAP BIR3–Smac/DIABLO complex. This ribbon 
representation is comprised of residues 258–346 of XIAP’s BIR3 domain complexed with 
residues 1’ to 4’ of Smac/DIABLO’s N terminus (Liu et al., 2000). 
A study by Nikolovska–Coleska and colleagues aimed to identify small molecule inhibitors 
of XIAP by mainly focusing on the BIR3 region as they believed the BIR3 domain has a 
critical role in apoptosis inhibition based on: (i) BIR3 binding to caspase 9 thereby trapping 
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caspase 9 in a monomeric inactive form and having the potential to inhibit caspase 9 
mediated apoptosis as well as (ii) BIR3 binds to Smac/DIABLO and inhibits the pro–
apoptotic activity. Nikolovska–Coleska and colleagues proposed that small molecule 
inhibitors which bind to XIAP’s BIR3 domain can increase cells’ sensitivity to apoptotic 
stimuli via promoting caspase 9 activation as well as Smac/DIABLO’s pro–apoptotic activity 
(Nikolovska–Coleska et al., 20041). 
1.5.2. BIR3 inhibition of XIAP leads to apoptosis 
It has been shown that XIAP over expression renders the cancer cells resistant to drug–
induced apoptosis. The binding of embelin to BIR3 inhibits the initiator caspase 9 and 
effector caspases 3 and 7. Embelin can therefore attenuate or block the protective effects of 
XIAP and enhance chemodrug–induced apoptosis. Nikolovaska–Coleska and colleagues 
showed that embelin is a fairly potent inhibitor of XIAP and suggested that its anti–cancer 
activity is mediated at least in part by its direct binding to XIAP and inhibition of the anti–
apoptotic function of XIAP protein in cancer cells (Nikolovska–Coleska et al., 20042). 
Other studies focusing on the development of embelin derivative compounds identified new 
and potent XIAP inhibitors targeting the BIR3 domain as they display enhanced properties 
within human cancer cells when used in combination with pro–apoptotic drugs (Ziedan et al., 
2008). 
 
1.6.  Nanotechnology for targeted delivery of anti–cancer drugs  
1.6.1. Goal of cancer therapy 
The therapeutic goal in cancer treatment is to trigger tumour–selective cell death (Sellers and 
Fisher, 1999). Cancer treatment most often results in the non–specific distribution of 
chemotherapeutic drugs and is taken up by both cancerous and non–cancerous cells (Sinha et 
al., 2006; Yih and Al–Fandi, 2006; Cho et al., 2008). These drugs can therefore also destroy 
non–cancerous cells (Yih and Al–Fandi, 2006). This gives rise to excessive and increased 
systemic toxicities and other adverse effects (Sinha et al., 2006; Cho et al., 2008). Therefore, 
traditional chemotherapy in some cases is not successful (Yih and Al–Fandi, 2006). For 
cancerous cells to be eliminated rapidly the anti–cancer drugs must be extensively distributed 
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to target the affected organs and tissues. Consequently, large quantities of the anti–cancer 
drug need to be administered (Sinha et al., 2006). 
Ideally an effective cancer treatment would result in the anti–cancer drug reaching the desired 
tumour after administration by penetrating the body’s barriers while maintaining minimal 
loss of their activity while circulating through the body. Upon reaching the desired tumour, 
the anti–cancer drugs should be able to selectively kill the cancerous cells without affecting 
the non–cancerous cells. These strategies can improve patient survival and quality of life by 
increasing intra–cellular concentrations of anti–cancer drugs, whilst reducing the dose 
limiting toxicities (Cho et al., 2008). 
Conventionally anti–cancer drugs may either be administered orally or via intravenous routes. 
Both these methods have disadvantages but traditional intravenous routes are more 
problematic compared to the oral delivery method. Some conventional intravenous drugs 
have low specificity thereby resulting in harmful effects to healthy tissues (Sinha et al., 2006; 
Yih and Al–Fandi, 2006). 
When searching for appropriate carriers for drug delivery systems, the main issues to 
consider are knowledge of drug incorporation and release, formulation stability and shelf life, 
biocompatibility, biodistribution and targeting as well as functionality (de Jong and Borm, 
2008). In vivo delivery of therapeutic agents to cancerous targets must overcome drug 
resistance at the cancerous level due to physiological barriers, drug resistance, 
biotransformation and clearance of anti–cancer drugs in the body (Brigger et al., 2002). 
The field of Nanotechnology is emerging as a technology that can facilitate allows for 
targeted delivery of anti–cancer drugs to the site of interest. The use of nanoparticles as 
delivery vehicles for targeted delivery of drugs is generating much interest. Figure 1.9 is a 
graphical representation of nanoparticles that can be used successfully as targeted delivery 
vehicles. Anti–cancer drug(s) can be conjugated along with a targeting peptide which 
specifically bind to a cell surface receptor expressed exclusively on the target cancer cells. 
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Figure 1.9: Structure of a nanoparticle for targeted drug delivery. From the 
illustration it can be observed that nanoparticles may be conjugated with targeting 
peptides (for recognition purposes) and anti–cancer drugs (for apoptosis induction). The 
targeting peptide and anti–cancer drug used in the conjugation experiments are specific 
for the cancer of interest [adapted from Cho et al., 2008]. 
According to Aina and colleagues peptides, peptidomimetics or small molecules are more 
effective targeting agents in cancer treatment and are therefore regarded as an alternative tool 
for targeted anti–cancer treatment therapies (Aina et al., 2007). These molecules are 
chemically stable, small and easy to synthesize. These molecules can easily be conjugated to 
radionuclides, cytotoxic drugs or toxins. 
When comparing the effect of peptides and antibody conjugated nanoparticles, Zambre and 
colleagues synthesized a series of antibody EGFR and EGFR–peptide conjugated gold 
nanoparticles to investigate the in vivo EGFR targeting characteristics of the conjugates in 
pancreatic tumour bearing SCID mice models. During their investigation, they observed that 
the peptide conjugate gold nanoparticles displayed high in vivo mobility and targeted the 
pancreatic tumour effectively (Zambre et al., 2009). Therefore, peptides would serves as a 
better option as a delivery agents due to their excellent tissue penetration, essy synthesis, easy 
conjugation to drugs and short oligonucleotides (Shadidi and Sioud, 2002). 
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1.6.2. Nanoparticles and drug delivery 
Advantages of drug delivery systems include improved solubility and biodistribution as well 
as in vivo stability. Loading of pharmaceutical drugs onto the drug delivery system, allows 
for controlled release of the drug while at the same time maintaining the drug level within the 
therapeutic dose (Ghosh et al., 2008). 
Nanoparticles have the potential to fulfil the requirements for effective drug carrier systems. 
For delivery of anti–cancer drugs to the targets to be effective, nanoparticles should remain in 
the blood stream for a significant period of time without the possibility of elimination (Cho et 
al., 2008) or destruction.  
Nanoparticle delivery of anti–cancer drugs to respective target tissues may be achieved in 
two ways, either via active or passive targeting (Sinha et al., 2006) where a combination of 
both targeting strategies will allow for an ideal carrier with regards to in vivo drug delivery 
(Ghosh et al., 2008). 
Passive targeting occurs when unhealthy tissues, due to extravasion via leaky blood vessels 
(Ghosh et al., 2008) allow for accumulation of nanocarriers due to their enhanced 
permeability and retention effect (Garcia et al., 2007). On the other hand, active targeting 
present ligands on the carrier surface for specific recognition by cell surface receptors (Ghosh 
et al., 2008) for conjugation purposes (Garcia et al., 2007).  
Therefore, the main goals of using nanoparticles in drug delivery would be based on the 
efficiency as well as specific in vivo delivery without toxicity. In relation to this, the dose 
delivered as well as the therapeutic efficacy may be measured accurately as well as non–
invasively over time (Cai et al., 2008). 
Nanoparticles may be defined as submicronic colloidal systems (Brigger et al., 2002; Cho et 
al., 2008). Their submicron sizes range from 3 to 200 nm (Cho et al., 2008). Nanoparticles 
may be composed of lipids, viruses, ceramics, metals as well as organometallic and biological 
compounds (Yin and Al–Fandi, 2006; Cho et al., 2008). 
Nanoparticle structures may be spherical, branched or shell shaped where each structure 
offers unique characteristics which makes them appropriate drug delivery candidates for 
specific therapies (Yih and Al–Fandi, 2006). Nanoparticles may consist of three layers 
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namely the surface, shell and core where the surface area is often functionalized and the 
shells material may be added intentionally (Christian et al., 2008).  
Anti–cancer drugs may be loaded onto nanoparticles via encapsulation, surface attachment or 
entrapping. It must be noted that the attachment technique is determined by the nanoparticles 
architecture and material, drug type as well as the targeted location. Nanoparticles are 
regarded as an attractive tool for biomedical purposes based on their unique features which 
include their large surface–to–mass ratio, their quantum properties as well as their ability to 
absorb and carry other compounds (de Jong and Borm, 2008). 
1.6.3. Nanoparticles as drug carriers 
By using nanoparticles for delivery of anti–cancer drugs, it provides a more effective and less 
harmful solution to overcome some of the problems arising from conventional anti–cancer 
drug delivery methods including severe toxic side effects on healthy organs, difficulties in 
clinical administration, drug resistance and limited access of the drug to the tumour sites 
(Sinha et al., 2006; Yih and Al–Fandi, 2006; Utreja et al., 2010).  
For successful drug delivery, nanoparticles are required to transport anti–cancer drugs to the 
targeted area where upon reaching the targeted area, the anti–cancer drug will be released. 
Therefore for successful and effective drug delivery, biologically inert nanoparticles are 
required to be formulated with the intention of both transport and release of the anti–cancer 
drugs (de Jong and Borm, 2008). Nanoparticles may also act at a cellular level where they 
may be endocytosed or phagocytosed by cells. This results in internalization of the 
encapsulated anti–cancer drug by the cells (Brigger et al., 2002). 
With regard to drug delivery, the primary goals for research into nanobiotechnologies should 
focus on specific drug targeting and delivery, reduced toxicity while maintaining therapeutic 
effects, greater safety and biocompatibility as well as faster development with regard to new 
and safer medicines. The requirements for appropriate carriers in drug delivery systems 
include knowledge of drug incorporation and release, stability and shelf life, 
biocompatibility, biodistribution and targeting as well as functionality (de Jong and Borm, 
2008). 
According to de Jong and Borm, a major challenge in drug delivery is getting the drug to the 
targeted area without potentially affecting the uninfected area. Therefore the full use of 
cytotoxic chemotherapeutics is limited due to their therapeutic potential (de Jong and Borm, 
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2008). Appropriately designed nanoparticles may act as a drug vehicle that is able to target 
cancerous targets as well as protecting the anti–cancer drug from premature activation during 
the transport process (Brigger et al., 2002). Increased local drug concentrations, as a result of 
these forms of targeted drug delivery, provides strategies for more specific therapy. 
Nanoparticles have specific characteristics that enable these strategies. These characteristics 
include their small size, binding and stabilization of proteins as well as lysosomal escape post 
endocytosis (de Jong and Borm, 2008). 
 
1.7.Aims of this study 
The objective of this study was to develop gold nanoparticles that can be used for targeted 
delivery of emeblin to cancer cells to improve the effects of pro–apoptotic drugs. This was 
achieved by biconjugating gold nanoparticles with embelin and a cancer specific targeting 
peptide. 
 
1.8.Thesis outline 
The remainder of this thesis is divided as follows: Chapter 2 describes the materials and 
methods applied in this work, Chapter 3.1 describes Evaluating the expression levels of XIAP 
in human cancer cell lines, Chapter 3.2 describes Evaluating the apoptotic effects of ceramide 
as an apoptotic inducer, Chapter 3.3 describes Cloning of XIAP into a His–tagged expression 
system, Chapter 3.4 describes Affinity purification of recombinant His–XIAP, Chapter 3.5 
describes Affinity purification for recombinant GST–XIAP, Chapter 3.6 describes Evaluating 
the interaction between recombinant GST–XIAP protein and embelin and embelin conjugated 
nanoparticles by Isothermal Titration Calorimetry and Chapter 4 summarizes the findings. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1. Materials used and suppliers         
2.1.1 List of kits used         
2.2. Solutions and buffers          
2.3. Cell culture           
2.3.1 Thawing MCF7 and HepG2 cells       
2.3.2 Trypsinization of MCF7 and HepG2 cells      
2.3.3 Seeding of cells         
2.3.4. Synthesis of embelin conjugated nanoparticles     
2.4. Synthesis of embelin conjugated nanoparticles      
2.5. Investigating the toxicity of embelin and embelin conjugated nanoparticles  
2.6. Investigating the concentration and percentage of gold in treated cancer cells by 
Inductively Couples Plasma–Optical Emission Spectrometry (ICP–OES)    
2.7. Investigating uptake of nanoparticles in treated cancer cells by transmission electron 
microscopy (TEM)          
2.8. Statistical analysis          
2.9. RNA isolation           
2.9.1 Agarose electrophoresis of RNA       
2.10. cDNA synthesis          
2.11. Primers           
2.12. Polymerase chain reaction (PCR) amplification of DNA     
2.13. Agarose gel electrophoresis of PCR product       
2.14. Gel purification of amplified PCR product       
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2.15. DNA cloning           
2.15.1 pGEM®–T Easy vector system       
2.15.2 Ligation of PCR product into pGEM®–T Easy vector    
2.15.3 Transformation of competent E. coli MC1061 competent cells   
2.15.4 Colony PCR amplification        
2.15.5 Culturing of transformed MC1061 E. coli cells     
2.15.6 Plasmid DNA isolation and purification      
2.15.7 Restriction digestion of pGEM–XIAP       
2.16. DNA sub–cloning          
2.16.1 pET28a Cloning Vector        
2.16.2 Restriction Digestion of pET28a       
2.16.3 Ligation of the released pGEM–XIAP product into the pET28a vector  
2.16.4 Transformation of BL21 (DE3) pLysS E. coli competent cells with pET28a–
XIAP construct         
2.16.5 Colony PCR amplification        
2.16.6 Culturing of transformed BL21 (DE3) pLysS E. coli cells    
2.17. Mini expression screen for recombinant His–XIAP protein      
2.18. Purification of recombinant His–XIAP protein      
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2.19.3 Expression of GST–XIAP recombinant protein     
2.19.4 Cell extract preparation and protein purification as per BugBuster® GST–
Bind purification kit         
2.20. Protein extraction from cultured human cancerous cells     
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2.1. Materials used and suppliers 
Materials        Suppliers 
Acetic Acid        Merck 
40 % Acrylamide Bis Solution 37:5:1    Bio–Rad  
Actin Antibody       Santa Cruz 
Agarose        Whitehead Scientific 
Ammonium Persulphate      Merck 
Ampicillin        Roche 
APOPercentage Dye       bioclor 
Bacterological Agar       Merck 
Boric Acid        Merck 
Bovine Serum Albumin (BSA)     Roche 
Bradford Reagent       Bio–Rad  
Calcium Chloride       Merck 
Cesium Chloride       Roche 
Coomassie Brilliant Blue R–250     Sigma–Aldrich 
CytoBuster™ Protein Extraction Reagent    Novagen 
Diethylpyrocarbonate (DEPC)     Merck 
Dithiothreitol (DTT)       Fermentas 
Dimethyl Sulfoxide (DMSO)      Sigma–Aldrich 
Dulbecco’s Modified Eagle’s Medium (DMEM)   Invitrogen 
DreamTaq™ Green PCR Master Mix (2X)    Fermentas 
Embelin        Merck 
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Embelin        Sigma–Aldrich 
Ethanol        Merck 
Ethidium Bromide       Merck 
Ethylene Diamine Tetra–Acetic Acid (EDTA)   Merck 
10X FastDigest Green Buffer      Fermentas 
FastDigest® Xho1 Restriction Enzyme    Fermentas 
Fetal Bovine Serum (FBS)      Invitrogen  
Glutaraldehyde       Sigma–Aldrich  
Goat Anti–Mouse IgG–HRP Antibody: sc–2031   Santa Cruz 
6X Gel Loading Dye       Fermentas 
GeneRuler™ 1 kb DNA Ladder     Fermentas 
Glycerol        Merck 
Glycine        Merck 
Hydrochloric Acid       Merck 
Isopropanol (Propan–2–ol)      Merck 
Isopropyl β–D–1–thiogalactopyranoside (IPTG)   Fermentas 
Kanamycin sulphate       Roche 
Manganese Chloride       Merck 
Methanol        Merck 
N–Acetyl–D–Sphingosine (C2 Ceramide)    Sigma–Aldrich 
N–Acetyl–D–Sphingosine (C2 Ceramide)    Merck 
Nitric Acid        Merck 
Nde1 Restriction Digestion Enzyme     Fermentas 
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Nuclease Free Water       Fermentas 
PageRuler™ Unstained Protein Ladder    Fermentas 
Paraformaldehyde       Sigma–Aldrich  
pGEM®–T Easy Vector Systems     Promega 
Penicillin–Streptomycin (500 Units:5 000 µg/ml)   Invitrogen 
pET28a Vector       Novagen 
Potassium Acetate       Merck 
Potassium Chloride       Merck 
Spectra™ Multicolor Broad Range Protein Ladder   Fermentas 
Sodium Chloride       Merck 
Sodium Dodecyl Sulphate (SDS)     Merck 
Sodium Hydroxide       Merck 
SuperSignal® West Pico Chemiluminescent Substrate  Thermo Scientific 
T4 DNA Ligase       Fermentas 
T4 DNA Ligase Buffer      Fermentas 
N,N,N’,N’–Tetramethylethylenediamine (TEMED)   Sigma–Aldrich 
Thrombin        Sigma–Aldrich 
Tris (hydroxymethyl) aminoethane (Tris)    Merck 
Trypsin        Invitrogen 
Tryptone Powder–Pancreatic Casein Powder    Merck 
Tween20        Merck 
Urea         Merck 
XIAP Antibody       Santa Cruz 
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pGEX–XIAP Construct      Addgene 
Yeast Extract Powder       Merck 
 
2.1.1. List of kits used 
First Strand cDNA Synthesis Kit for RT–PCR (AMV)  Roche 
HIS–Select® Nickel Affinity Gel     Sigma–Aldrich 
Novagen GST–Bind™ Kit      Merck 
Novagen Ni–NTA His Bind® Resins    Merck 
NucleoSpin® Extract II PCR Clean–Up Gel Extraction  Machery–Nagel 
NucleoSpin® TriPrep Kit      Machery–Nagel 
Wizard® Plus SV Miniprep DNA Purification System  Promega 
 
2.2. Solutions and buffers 
Ammonium Persulphate: 10% stock prepared in distilled water, filter sterilized, stored at –
20 ºC 
Ampicillin: 100 mg/ml stock prepared in distilled water, filter sterilized and stored at –20 ºC 
Coomassie Stain: 0.25% Coomassie Blue R–250, 40% Ethanol, 10% Acetic Acid 
C2–ceramide: 0.005 M stock prepared in DMSO, filter sterilized, stored at –20 ºC 
DEPC Treated Water: 1 ml dimethyl dicarbonate per 1L distilled water, incubated at 22 ºC 
overnight, autoclaved 
Destaining Solution: 10% Acetic Acid and 10% Methanol prepared in distilled water 
DTT: 1 M stock prepared in distilled water, filter sterilized, stored at –20 ºC 
Embelin stock: 0.03 M stock prepared in DMSO, stored at –20 °C 
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Hydrochloric Acid: 2% (v/v) prepared in distilled water 
Gluteraldehyde: 2.5% (w/v) prepared in distilled water, stored at 4 °C 
IPTG: 1 M stock prepared in distilled water, filter sterilized, stored at –20 ºC 
Kanamycin sulphate: 100 mg/ml stock solution prepared in distilled water, filter sterilized, 
stored at –20 ºC 
Luria Agar: 10 g Tryptone, 5 g NaCl, 5 g Yeast Extract prepared in 1L distilled water 
Luria Broth: 10 g Tryptone, 5 g NaCl, 5 g Yeast Extract, 15 g Bacteriological Agar prepared 
in 1L distilled water 
Nitric Acid: 70% (v/v) prepared in distilled water 
Paraformaldehyde: 4% (w/v) prepared in half the final volume distilled water, heat to 60 
°C, adjust pH to 7.4, make up to final volume, filter sterilize, stored at 4 °C 
0.5 M Phosphate Buffer: 71 g di–sodium hydrogen phosphate, 69 g sodium dighydrogen 
phosphate prepared in 1L ultrapure (i.e. 18 M Ω) water  
0.5 M Phosphate Buffer–DMSO: 71 g di–sodium hydrogen phosphate, 69 g sodium 
dighydrogen phosphate, 0.15% (v/v) DMSO prepared in 1L ultrapure (i.e. 18 M Ω) water 
10X PBS: 81.8 g NaCl, 2 g KCl, 18 g Na2HPO4, 2.5 g KH2PO4 prepared in 1L distilled water 
1X PBS: dilute 10X PBS according to the dilution 1:10 (v/v) in distilled water 
10X Running Buffer: 144 g Glycine, 30 g Tris, 10 g SDS prepared in 1L distilled water 
1X Running Buffer: dilute 10X Running Buffer according to the dilution 1:10 (v/v) in 
distilled water 
2X Sample Buffer: 4% SDS, 20% glycerol, 100 mM Tris–HCl (pH 6.8), 0.2% bromophenol 
blue, 200 mM DTT 
12% Separating Buffer: 40% Polyacrylamide, 1.5 M Tris–HCl (pH 8.8), 10% Ammonium 
Persulphate, 10% SDS, 0.002% TEMED 
5% Stacking Buffer: 40% Polyacrylamide, 1 M Tris (pH 6.8), 10% Ammonium 
Persulphate, 10% SDS, 0.002% TEMED 
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SDS: 10% prepared in distilled water 
1X Transfer Buffer: 3.03 g/l Tris, 14.42 g/l Glycine, 40% Methanol 
10X TBE: 1M Tris–HCl, 0.5 M EDTA 
1X TBE: dilute 10X TBE according to the ration 1:10 (v/v) in distilled water 
TE: 10mM Tris–HCl (pH 8), 1 mM EDTA 
1X TBSTween: 1 M Tris, 5 M NaCl, 1 ml/l Tween 20 
1X TBSTween–BSA: 0.3 g BSA in 1L TBSTween 
1X TBSTween–Milk: 0.5 g low fat milk powder in 1L TBSTween 
 
2.3. Cell culture 
MCF7 cells (mammalian breast cancer cell line supplied by ATCC®) and HepG2 cells 
(mammalian liver cancer cell line supplied by ATCC®) were cultured in complete media (i.e. 
Dulbecco’s Modified Eagle’s Medium (DMEM) media supplemented with 10% Fetal Bovine 
Serum (FBS) and 1% penicillin–streptomycin). All cell culture reagents were obtained from 
Invitrogen. 
2.3.1. Thawing MCF7 and HepG2 cells 
DMEM complete media (5 ml) was placed at 4 °C. Frozen vials of MCF7 and HepG2 cells 
were removed from the –150 °C freezer and thawed in a 37 °C water bath. Cells were 
transferred to 15 ml tubes containing 5 ml pre–cooled DMEM complete media and 
centrifuged at 3 000×g for 5 minutes. The supernatant was decanted and pelleted. Cells were 
re–suspended in 5 ml complete media. The latter was transferred to 25 cm2 tissue culture 
flasks. The flask was incubated at 37 °C with 5% CO2 until 70–90% confluency was reached. 
2.3.2. Trypsinization of MCF7 and HepG2 cells 
When cells reached confluency the media were discarded and cells were washed once with 
phosphate buffered saline (PBS). The PBS was discarded and cells were trypsinized with 2X 
and 1X trypsin for MCF7 and HepG2 cells respectively. Cells were incubated at 37 °C for 2–
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3 minutes. DMEM complete media was added to the flask to stop trypsinization. The cells 
were collected by centrifugation at 3 000×g for 3 minutes. 
2.3.3. Seeding of cells 
Once confluency was reached the cells were trypsinized and re–suspended in 10 ml DMEM 
complete media. Cells were counted with the use of the Countess™ automated cell counter 
(Invitrogen). Cells were seeded at a density of 2×10
5
 live cells/ml for 6 well plates and 5×10
5
 
live cells/ml for a 25 cm
2
 flask. 
2.3.4. Freezing of MCF7 and HepG2 cells 
For long term storage the cells were trypsinized and harvested by centrifugation. The cell 
pellet was re–suspended in DMEM complete media containing 10% DMSO. The latter was 
aliquoted into 2 ml cryo–vials and stored at –150 °C. 
 
2.4. Synthesis of embelin conjugated nanoparticles 
Gold nanoparticles (AuNPs) (14 nm in size) were synthesized and provided by Dr. Franklin 
Keter (Mintek). Two variants of the AuNPs were prepared. Embelin was conjugated to our 
batch of the 14 nm AuNPs to form AuNP–E conjugate. Embelin and a cancer targeting 
peptide LTVSPWY (Shadidi and Sioud, 2003
1
) were conjugated to a second batch forming a 
AuNP–P–E biconjugate. Biconjugation was carried out using the ratio of 
embelin:peptide:PEG–OH of 10%:1%:89%.  
 
2.5. Investigating the toxicity of embelin and embelin conjugated nanoparticles 
MCF7 breast and HepG2 liver cancer cells were seeded into 6–well plates (Section 2.3.3) and 
cultured to 60 – 70% confluent. Cells were treated for 24 hours in triplicate in one of eight 
treatment options: 50 µM embelin, 5 nM AuNP, 5 nM AuNP–E or 5 nM AuNP–P–E and co–
treatments involving the above mentioned treatments with 50 µM ceramide. 
Morphological changes were studied using the Nikon TMS light microscope with a 20X 
magnification. Images were captured with the aid of the Leica Firecam EC3 Camera. 
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Apoptosis was assayed by flow cytometry using the FACScan (BD Biosciences) according to 
the protocol as described by Meyer and colleagues (2008). 
 
2.6. Investigating the concentration and percentage of gold in treated cancer cells by 
Inductively Coupled Plasma–Optical Emission Spectrometry (ICP–OES) 
MCF7 breast and HepG2 liver cancer cells were seeded into 6–well plates (Section 2.3.3) and 
cultured to 60 – 70% confluent. Cells were treated for 24 hours in duplicate with 5 nM 
AuNP–E and 5 nM AuNP–P–E. Cells were trypsinized (Section 2.3.2) and pellets were 
washed with PBS. For control purposes pellets of AuNP–E and AuNP–P–E were collected by 
centrifugation. These pellets were washed with PBS. Cell pellets, of treated cells and 
controls, were re–suspended in 70% nitric acid (2ml) and digested for two hours at 90 °C. 
The final volume was made up to 10 ml by addition of 2% hydrochloric acid. The 
concentration and percentage of AuNP in treated cells were determined using the Varian 
1600 ES instruments and ICP expert 11 software. The experiments were performed by the 
Environmental and Nanosciences Group (Department of Chemistry, University of the 
Western Cape). 
 
2.7. Investigating uptake of nanoparticles in treated cancer cells by Transmission 
Electron Microscopy (TEM) 
MCF7 breast and HepG2 liver cancer cells were seeded into 25 cm
2
 flasks (Section 2.3.3) 
and cultured to 60 – 70% confluent. Cells were treated for 24 hours with 5 nM AuNP and 5 
nM AuNP–P–E + 50 µM ceramide co–treatment. 
The supernatant of the treated cells were collected and pelleted by centrifugation. The 
supernatant of the latter was discarded and pellets were stored on ice. Adherent treated cells 
were washed with PBS and pelleted by centrifugation. Pellets from the respective treatments 
were collected and added to the adherent cells. To the latter 4% paraformaldehyde (2 ml) was 
added and flasks were placed on a shaker for 15 minutes at 4 °C. Cell scrappers were used to 
gather cells. Cells were transferred to labelled 15 ml tubes and pellets were collected by 
centrifugation at 2 000 rpm for 10 minutes at 4 °C. Pellets were re–suspended in 2.5% 
gluteraldehyde (100 µl). The uptake of nanoparticles was assessed using the JEOL JEM–
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1011 Electron Microscope and cis analysis program iTEM imaging software. Analysis was 
performed by the National Health Laboratory Services (Tygerberg Hospital, Cape Town). 
 
2.8. Statistical analysis 
All data are presented as mean ± SD. Statistical analysis was performed using one–way 
ANOVA, followed by Tukey’s Test. P–values were P<0.05. 
 
2.9. RNA isolation 
The isolation of RNA was carried out with the use of Machery–Nagel’s NucleoSpin® Tri 
Prep Kit according to the manufacturer’s guide. 
MCF7 cells were cultured in DMEM complete media (Section 2.3). Upon reaching 
approximately 80% confluency MCF7 cells were trypsinized (Section 2.3.2). The cell pellet 
was washed with PBS to remove traces of the 2X trypsin prior to RNA isolation. 
The cells were lysed by addition of 350 µl PR1 buffer and 7 µl 1 M DTT. The cells were 
vortexed vigorously for 1 minute. The cell suspension was filtered through a NucleoSpin® 
Filter (violet ring) by transferring the cell suspension onto the filter and centrifuged at 
11 000×g at 25 °C. The NucleoSpin® Filter was discarded and 350 µl 70% ethanol was 
added to the homogenized lysate (filtrate) and mixed gently. For each preparation, a 
NucleoSpin® TriPrep Column (light blue ring) was placed in a Collection Tube onto which 
the lysate was loaded. The samples were centrifuged at 11 000×g for 30 seconds at 25 °C. 
After centrifugation, the NucleoSpin® TriPrep Column was placed into a new Collection 
Tube.  
For RNA extraction: rDNase reaction mixture was prepared first by addition of reconstituted 
rDNase (10 µl) and reaction buffer for rDNase (90 µl) into a sterile 0.2 ml PCR tube. From 
the rDNase mixture, 95 µl was added directly onto the center of the silica membrane of the 
column. The column was incubated at room temperature for 15 minutes. A volume of 200 µl 
Buffer RA2 was added to the NucleoSpin® TriPrep Column and centrifuged at 11 000 ×g for 
30 seconds at 25 °C. The NucleoSpin® TriPrep Column was placed into a new Collection 
Tube. 
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A volume of 600 µl Buffer RA3 was added to the NucleoSpin® TriPrep Column and 
centrifuged at 11 000×g for 30 seconds at 25 °C. The flow through was discarded and the 
NucleoSpin® TriPrep Column was returned to the Collection Tube. A volume of 250 µl 
Buffer RA3 Buffer was added to the NucleoSpin® TriPrep Column and centrifuged at 
11 000×g for 2 minutes at 25 °C. 
The NucleoSpin® TriPrep Column was placed into a sterile 1.5 ml RNase–free Collection 
Tube. RNase free water was added to the NucleoSpin® TriPrep Column and centrifuged at 
11 000×g for 1 minute. The flow through collected contained the total RNA. The RNA 
sample was quantified using the NanoDrop ND–100 Spectrophotometer (NanoDrop 
Technologies).  
2.9.1. Agarose gel electrophoresis of RNA 
Agarose gels with a percentage of 1% (w/v) were prepared by boiling appropriate amounts of 
agarose powder in 1X TBE until dissolved. Upon cooling ethidium bromide was added to a 
final concentration of 1 µg/ml. The prepared 1% agarose were poured into gel casting trays 
and allowed to solidify. RNA was electrophoresed on a 1% agarose gel to confirm its 
integrity. Isolated RNA (3.5 µg) was diluted with 6X loading buffer and heated at 95 °C for 2 
minutes before loading into the wells. Electrophoresis was carried out at 100 V in 1X TBE 
electrophoresis buffer. After electrophoresis, the gel was viewed by ultra–visible illumination 
using a UV trans–illuminator. The gel image was captured with an image capturing system 
(Kodak Digital Science 1D). 
 
2.10. cDNA synthesis 
Roche’s First Strand cDNA Synthesis Kit for RT–PCR (AMV) was used for cDNA synthesis 
according to the manufacturer’s guide: 
An amount of 0.5 µg of isolated RNA was placed into a sterile 1.5 ml centrifuge tube. The 
following reagents were added to the tube: 
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Table 2.1: Reagents utilized in cDNA synthesis reaction 
Reagent Final Concentration 
10X Reaction Buffer 1X 
25 mM MgCl2 5 mM 
Deoxynucleotide Mix 1 mM 
Oligo–p(dT)15 Primer 0.8 µg/µl 
RNase Inhibitor 50 Units 
AMV Reverse Transcriptase 20 Units 
Sterile Water Variable 
RNA Sample Variable 
 
For secondary structure denaturation, the RNA sample was placed on a 65 °C heating block 
for 15 minutes and subsequently placed on ice for 5 minutes. RNA was added to the mixture 
followed by a brief centrifugation at 13 200×g for 5 seconds. The reaction mixture was 
incubated at 25 °C for 10 minutes followed by 42 °C for 60 minutes. The reaction was then 
incubated at 99 °C for 5 minutes followed by 4 °C for 5 minutes. The cDNA was quantified 
using the NanoDrop ND–100 Spectrophotometer (NanoDrop Technologies). 
 
2.11. Primers 
XIAP gene specific primers for PCR amplification were designed from XIAP’s coding region 
with an accession number NM_001167.2. The forward primer was designed to include the 
restriction enzyme Nde1 (CATATG) whereas the reverse primer was designed to include the 
restriction enzyme Xho1 (CTCGAG). These gene specific primers were synthesized and 
purchased from Inqaba Biotech. 
Table 2.2: XIAP gene specific primers used in PCR reactions 
Primers                            Sequence 
Forward                             5’ – GACTCATATGACTTTTAACAGTTTTGAAGGA – 3’ 
Reverse                             5’ – GACTCTCGAGAGACATAAAAATTTTTTGCTTGAA – 3’ 
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Table 2.3: PCR parameters as at 35 cycles 
Parameter Temperature Time 
1. Initial Denaturation 95 °C 3 minutes 
2. Denaturation 94 °C 30 seconds 
3. Annealing 61 °C 30 seconds 
4. Elongation 72 °C 45 seconds 
5. Final Elongation 72 °C 10 minutes 
6. Incubation 4 °C ∞ 
 
2.12. Polymerase chain reaction (PCR) amplification of DNA 
PCR reactions were carried out using Fermentas 2X DreamTaq™ Green Buffer according to 
the manufacturer’s guide. PCR reactions were prepared according to Table 2.4 with the use 
of gene specific primers (Table 2.2). The parameters for PCR reactions were according to 
Table 2.3. 
Two 1% agarose gels were electrophoresed. The first gel was viewed and images were 
captured with an image capturing system (Kodak Digital Science 1D). The second gel was 
used for electrophoresis of the remaining PCR product. This was visualized with a 360 nm 
UV lamp before the band of interest was excised using a sterile blade and placed in a sterile 
1.5 ml microcentrifuge tube. The latter was stored at –20 °C.  
 
Table 2.4: Reagents utilized in PCR reaction 
Reagent Final Concentration 
Fermentas 2X DreamTaq™ 1X 
XIAP Forward Primer 0.4 µM 
XIAP Reverse Primer 0.4 µM 
DNA 0.8 µg/µl 
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2.13. Agarose gel electrophoresis of PCR product 
Amplified products were analysed post PCR amplification by electrophoresis of 1% agarose 
gels. Preparation and electrophoresis of 1% agarose gels as well as image capturing are as 
mentioned in Section 2.9.1.  
 
2.14. Gel purification of amplified PCR product 
Post PCR amplification, electrophoresis enabled visualization of fragments of interest. These 
bands were viewed using a 360 nm UV lamp and excised with a sterile blade. DNA was 
purified using Machery–Nagel’s NucleoSpin® Extract II PCR Clean–Up Gel Extraction Kit 
according to the manufacturer’s guide. 
The excised product of interest was transferred to a sterile 1.5 ml microcentrifuge tube and 
the weight of the agarose gel was determined. For each 100 mg of the 1% agarose gel 
containing the product of interest, 200 µl NT buffer was added. The sample was placed on a 
heating block at 50 °C for 10 minutes whilst vortexing at 2–3 minute intervals until the 
agarose dissolved completely. The solution was added to the Nucleospin® Extract II Column 
which was placed in a 2 ml Collection Tube. The tube was centrifuged at 11 000×g for 1 
minute and the flow through was discarded. A volume of 700 µl Buffer NT3 was added to the 
Nucleospin® Extract II Column and centrifuged at 11 000×g for 1 minute. The flow through 
was discarded. The tube was centrifuged for another 2 minutes at 11 000×g for complete 
removal of NT3 buffer. The Nucleospin® Extract II Column was placed in a sterile 1.5 ml 
microcentrifuge tube to which 50 µl NE Buffer was added and the column was incubated on 
the bench for 1 minute. The latter was centrifuged at 11 000×g for 1 minute. The collected 
DNA was quantified using the NanoDrop ND–100 Spectrophotometer (NanoDrop 
Technologies) and stored at –20 °C. 
 
2.15. DNA cloning 
2.15.1. pGEM®–T Easy vector system 
The pGEM®–T Easy cloning vector from Promega (Figure 2.1) was used. pGEM®–T Easy 
vector is a linearized vector system consisting of a single 3’–terminal thymidine overhang at 
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the vector’s ends. The thymidine overhangs function in improving the ligation efficiency of 
PCR products by preventing the vector from recircularizing. Hence it provides compatible 
overhangs for PCR products that have adenosine overhangs generated by thermostable 
polymerases.  
One of the best features of the pGEM®–T Easy vector is that it contains many restriction 
sites within the multiple cloning region. The multiple cloning region is flanked by recognition 
sites for the enzymes BstZ I, EcoR I and Not I. These enzymes provide the release of the 
insert when performing sub–cloning experiments. pGEM®–T Easy vectors are usually 
supplied with 2X Rapid Ligation Buffer which enable fast and effective incubation periods 
and increase the number of colonies post transformation. 
 
 
Figure 2.1: A circular map and sequence referencing points of pGEM®–T Easy vector 
system. 
2.15.2. Ligation of PCR product into pGEM®–T Easy vector 
The insert, i.e. XIAP PCR product, was purified and quantified using the NanoDrop ND–100 
Spectrophotometer (NanoDrop Technologies). 
The ligation reaction of XIAP’s PCR product and pGEM®–T Easy vector was carried out 
with the use of Promega’s T4 DNA Ligase. The protocol for ligation was performed 
according to the manufacturer’s guide: 
The ligation reaction was set up according to the following equation: 
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[(ng of vector × kb size of insert) ÷ kb size of vector] × insert:vector ratio 
The recommended insert:vector ratio used was 3:1. The ligation reaction was prepared 
according to Table 2.5. The reactions were incubated at 4 °C overnight. 
 
Table 2.5: Reagents utilized in the ligation reaction of XIAP and pGEM®–T Easy 
Reagents Experiment Negative Control 
pGEM–T Easy Vector (4 
ng/µl) 
2 µl 2 µl 
XIAP Insert (13.9 ng/µl) 2 µl - 
Promega 2X Ligation 
Buffer 
10 µl 10 µl 
Nuclease Free Water 5 µl 7 µl 
T4 DNA Ligase (U/ µl) 1 µl 1 µl 
TOTAL (µl) 20 µl 20 µl 
 
2.15.3. Transformation of competent E. coli MC1061 competent cells 
Competent MC1061 E. coli cells were thawed on ice. To the ligation reactions, 100 µl of the 
competent cells were added. Both the experimental and negative control were incubated on 
ice for 20 minutes. Cells were heat shocked at 42 °C for 45 seconds followed by 5 minute 
incubation on ice. A volume of 900 µl pre–warmed Luria broth was added to each tube and 
the latter were incubated at 37 °C for 60 minutes whilst shaking at 700 rpm. After incubation 
100 µl of each reaction, were plated on agar plates that contained 100 µg/ml ampicillin. 
Plates were incubated at 37 °C overnight.  
2.15.4. Colony PCR amplification 
Post transformation and plating, random colonies were selected from the plates. These 
colonies were screened for the presence of the XIAP insert by colony PCR amplification. 
Each colony was inoculated in PCR reaction with a final volume of 25 µl where the colony 
selected served as the template. The parameters for the PCR reaction were the same as 
described in Section 2.12.  
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2.15.5. Culturing of transformed MC1061 E. coli cells 
Luria broth containing 100 µg/ml ampicillin was prepared. Colonies that screened positive 
for the XIAP insert (Section 2.15.4) were used to inoculate 5 ml prepared broth. The culture 
was incubated at 37 °C overnight whilst shaking at 170 rpm.  
 
2.15.6. Plasmid DNA isolation and purification 
From the overnight cultures 2.5 ml was removed and used for the preparation of 20% 
glycerol stocks (v/v). Glycerol stocks were stored at –80 °C. Plasmid DNA was isolated and 
purified from remaining overnight cultures (approximately 25 ml) using Promega’s Wizard® 
Plus SV Miniprep DNA Purification System according to the manufacturer’s guide. 
The overnight bacterial culture was removed from the 37 °C incubator. Approximately 25 ml 
of the culture was centrifuged at 3 500×g for 15 minutes. The supernatant was discarded and 
the pellet was resuspended in 250 µl Cell Resuspension Solution by vortexing. A volume of 
250 µl Cell Lysis Solution was added to the latter and the tube was inverted 4 times. A 
volume of 10 µl Alkaline Protease Solution was added and the tube’s contents were mixed by 
inverting the tube 4 times. The cell suspension was incubated at room temperature for 5 
minutes. A volume of 350 µl Neutralization Solution was added and the solution was 
immediately mixed by inverting the tubes 4 times. The bacterial lysate was centrifuged at 
13 200×g for 10 minutes.  
The cleared lysate were transferred to a prepared Spin Column. The column was centrifuged 
at 13 200×g for a minute. The flow through was discarded and 750 µl Column Wash Solution 
was added to the Spin Column. Thereafter, the column was centrifuged at 13 200×g for 1 
minute. The flow through was discarded and 250 µl Column Wash Solution was added. The 
column was centrifuged at 13 200×g for 2 minutes. The Spin Column was transferred to a 
sterile 1.5 ml microcentrifuge tube. Plasmid DNA was eluted by addition of 100 µl Nuclease 
Free Water and centrifugation at 13 200×g at room temperature for 1 minute. The purified 
plasmid DNA was quantified using the NanoDrop ND–100 Spectrophotometer (NanoDrop 
Technologies) and stored at –20 °C. 
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2.15.7. Restriction digestion of pGEM–XIAP  
Restriction enzymes were used to subclone PCR amplified XIAP product from the vector 
pGEM–T Easy. pGEM–XIAP plasmid DNA was digested with Fermentas’ Xho1 FastDigest 
and Nde1 enzymes according to the manufacturer’s guide. 
For the first reaction, 1 µg of DNA was digested with 1 Unit of Xho1 FastDigest in the 10X 
FastDigest Green Buffer and incubated at 37 °C for 60 minutes. The Xho1 FastDigest was 
heat inactivated by incubation at 80 °C for 5 minutes. To the latter, 1 Unit of Nde1 enzyme 
was added and incubated at 37 °C overnight. The Nde1 enzyme was heat inactivated by heat 
inactivation at 65 °C for 30 minutes. 
 
2.16. DNA sub–cloning  
2.16.1. pET28a cloning vector 
The expression vector pET28a (Figure 2.2) was purchased from Novagen. pET vector 
systems are regarded as the most powerful systems that have been developed for both cloning 
and expression of recombinant proteins in E. coli. Target genes are cloned in pET plasmids 
under control of strong bacteriophage T7 transcription and translation signals which are 
optional. Another important benefit of this system is its ability to maintain target genes 
transcriptionally silent in the uninduced state. 
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Figure 2.2: A circular map and sequence referencing points of pET28a expression vector 
system. 
 
2.16.2. Restriction digestion of pET28a 
The pET28a expression vector was digested with Fermentas’ Xho1 FastDigest and Nde1 
enzymes as described in Section 2.15.7. The linearized vector was gel purified and quantified 
as described in Section 2.14. 
2.16.3. Ligation of the released pGEM–XIAP product into the pET28a vector 
The ligation of the product released from pGEM–XIAP into the linearized pET28a vector 
was performed using Promega’s T4 DNA ligase according to the manufacturer’s guide. The 
reactions were set up according to the following equation: 
[(ng of vector × kb size of insert) ÷ kb size of vector] × insert:vector ratio 
The recommended insert:vector ratio used was 3:1. The ligation reactions were prepared 
according to Table 2.6. 
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Table 2.6: Reagents used in ligation of pET28a expression vector and XIAP  
Reagents Experiment Enzyme Control Vector Only Control 
pET28a Vector (1.2 
ng/µl) 
8 µl 8 µl 8 µl 
XIAP Insert (1.6 
ng/µl) 
5 µl - - 
Fermentas 10X T4 
DNA Ligase Buffer 
2 µl 2 µl 2 µl 
Nuclease Free Water 4 µl 9 µl 10 µl 
T4 DNA Ligase 
(1U/µl) 
1 µl 1 µl - 
TOTAL (µl) 20 µl 20 µl 20 µl 
Reactions were mixed by pipetting, incubated at room temperature for 1 hour and finally 
incubated at 4 °C for overnight. 
 
2.16.4. Transformation of BL21 (DE3) pLysS E. coli competent cells with pET28a–
XIAP Construct 
Competent BL21 (DE3) pLysS E. coli cells were thawed on ice and 100 µl of the cells were 
added to the ligation reactions. All reactions were incubated on ice for 20 minutes. Cells were 
heat shocked at 42 °C for 45 seconds followed by 5 minute incubation on ice. A volume of 
900 µl pre–warmed Luria broth was added to each tube and the latter were incubated at 37 °C 
for 60 minutes whilst shaking at 700 rpm. After incubation 100 µl of each reaction was plated 
on agar plates that contained 50 µg/ml kanamycin sulphate. Plates were incubated at 37 °C 
overnight.  
2.16.5. Colony PCR amplification 
E. coli colonies were screened for the presence of the XIAP insert by colony PCR. The 
parameters for the PCR reaction were the same as described in Section 2.12.  
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2.16.6. Culturing of transformed BL21 (DE3) pLysS E. coli cells 
Luria broth containing 50 µg/ml kanamycin sulphate was prepared. Colonies that screened 
positive for the XIAP insert (Section 2.15.4) was used to inoculate prepared broth. The 
culture was incubated at 37 °C overnight whilst shaking at 170 rpm. From the overnight 
cultures, 20% glycerol stocks (v/v) were prepared and sored at –80 °C.  
 
2.17. Mini expression screen for recombinant His–XIAP protein 
Glycerol stocks containing BL21 (DE3) pLysS E. coli cells transformed with pET28a–XIAP 
were streaked out on Luria agar plates that contained 50 µg/ml kanamycin sulphate. Plates 
were incubated at 37 °C overnight. Single colonies were picked and cultured in 5 ml Luria 
broth containing 50 µg/ml kanamycin sulphate at 37 °C whilst shaking at 170 rpm for four 
hours. Aliquots of 1 ml were transferred to two separate 1.5 ml tubes where IPTG (1 mM) 
was added to one of the cultures (induced). No IPTG was added to the second culture 
(uninduced). Both tubes were incubated at 37 °C whilst shaking at 700 rpm for a further four 
hours. 
Cells were harvested by centrifugation at 13200 rpm for 10 minutes in a bench top centrifuge. 
The supernatant was discarded and pellets were re–suspended in 100 µl of 2X Sample Buffer. 
The suspension was briefly centrifuged on bench top centrifuge at top speed followed by 
incubation at 95 °C for five minutes. Samples were analysed by SDS–PAGE gel 
electrophoresis (Section 2.21). The clone that demonstrated the highest level of recombinant 
protein expression was selected for large scale expression and purification. Additional 20% 
glycerol stocks (v/v) were prepared for these clones. 
 
2.18. Purification of recombinant His–XIAP protein 
A volume of 100 µl of culture of the highest expressing clone of E. coli BL21 (DE3) cells 
(Section 2.16.6) was used to inoculate 100 ml Luria broth containing 50 µg/ml kanamycin 
sulphate. Cells were incubated at 37 °C for 16 hours whilst shaking at 170 rpm. A further 900 
ml Luria broth containing 50 µg/ml kanamycin sulphate was added to the primary culture and 
cells were incubated at 37 °C until OD600 was between 0.4 and 0.6. Expression of 
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recombinant protein was induced by the addition of IPTG to a final concentration of 1 mM 
and cells were incubated at 25 °C for a further 16 hours. 
Cultures were transferred to 250 ml propylene tubes and harvested by centrifugation at 
6000×g at 4 °C for 10 minutes. The pellets were either stored at –20 °C or processed further 
as described in Section 2.18.1. 
2.18.1. Cell extract preparation and protein purification as per Ni–NTA His–Bind® 
Resins 
Purification of recombinant XIAP was carried out using of Novagen’s Ni–NTA His–Bind® 
Resins according to the manufacturer’s guide. 
Once thawed the respective pellets were weighed to determine the volume of BugBuster 
reagent to be added. A Protease Inhibitor tablet was re–suspended in 3 ml BugBuster reagent. 
Thereafter, 1 µl Benzonase was added per 1 ml BugBuster re–suspension reagent. Pellets 
were allowed to dry and re–suspended in the respective volumes of re–suspension reagent. 
Cell suspensions were incubated on a slow shaking platform at room temperature for 20 
minutes. Cell suspensions were centrifuged at 16 000×g at 4 °C for 20 minutes. The insoluble 
debris were removed and used for batch purification under native conditions. The pellets 
were stored at –20 °C. 
A volume of 250 µl of 50 % Ni–NTA His–Bind slurry was added to 1 ml 1X Ni–BTA Bind 
Buffer and mixed gently. The resin was allowed to settle by gravity and 1 ml of the 
supernatant was removed. The 1 ml cleared lysate was added to the Ni–NTA His–Bind slurry 
and was mixed gently by shaking at 100 rpm at 4 °C for 60 minutes. The lysate–Ni–NTA 
His–Bind mixture was loaded onto a column with the bottom outlet capped. The bottom cap 
was removed to collect the through. The column was washed twice with 1 ml 1X Ni–NTA 
Wash Buffer and both flowthroughs were collected. The protein was eluted with 4 volumes 
of 2500 µl 1X Ni–NTA Elution Buffer. All four elutes along with the two washes and flow 
through were stored at –20 °C for 1D SDS PAGE gel electrophoresis (Section 2.21). The 
column was stored at 4 °C after 10 % ethanol was added. 
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2.19. Expression and purification of GST–XIAP protein 
The pGEX–XIAP construct was purchased from Addgene for expression and purification of 
the XIAP recombinant protein. E. coli containing the pGEX–XIAP construct was streaked on 
Luria agar plates containing 100 µg/ml ampicillin. Plates were incubated at 37 °C for 16 
hours. 
Two colonies from each plate were selected and used to inoculate Luria broth (30 ml) 
containing 100 µg/ml ampicillin. These cultures were incubated at 37 °C whilst shaking at 
170 rpm for 16 hours. 
Glycerol stocks (20 % v/v) were prepared from the overnight cultures and stored at –80 °C. 
The remaining cultures were used for plasmid DNA isolation and purification using 
Promega’s Wizard® Plus SV Miniprep DNA Purification System according to the 
manufacturer’s guide (Section 2.15.6). 
2.19.1. Transformation of E. coli BL21 (DE3) pLysS competent cells with the pGEX–
XIAP construct 
Competent BL21 (DE3) pLysS E.coli cells were thawed on ice and 100 µl of the cells were 
added per 2 µl GST–XIAP plasmid DNA (Section 2.16.4). A negative control consisting of 
100 µl of the cells only was used. All reactions were incubated on ice for 20 minutes. Cells 
were heat shocked at 42 °C for 45 seconds followed by 5 minute incubation on ice. A volume 
of 900 µl pre–warmed Luria broth was added to each tube and the latter were incubated at 37 
°C for 60 minutes whilst shaking at 700 rpm. Plates were incubated at 37 °C overnight. 
2.19.2. Expression screen for recombinant GST–XIAP protein 
Single colonies were selected from the plates and used to inoculate Luria broth (30 ml) 
containing 100 µg/ml ampicillin. Cultures were incubated at 37 °C whilst shaking at 170 rpm 
for four hours. Plates were stored at 4 °C. Glycerol stocks (20% v/v) were prepared from the 
cultures and stored at –80 °C. Aliquots (1 ml) were transferred into two separate 1.5 ml tubes. 
Isopropyl β–D–thiogalactopyranoside (IPTG) was added to one of the cultures (induced 
sample had a final optimized concentration of 0.2 mM IPTG) whereas no IPTG was added to 
the other sample (uninduced). Both tubes were incubated at 37 °C whilst shaking at 700 rpm 
for a further four hours. 
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Cells were harvested by centrifugation for 10 minutes centrifuge at 13 200 rpm in a bench 
top. The supernatant was discarded and pellets were re–suspended in 100 µl of 2X Sample 
Buffer. The suspension was briefly centrifuged in a bench top centrifuge at 13000 rpm 
followed by incubation at 95 °C for five minutes. Samples were analysed by SDS–PAGE gel 
electrophoresis (Section 2.21). The clone that demonstrated the highest level of recombinant 
protein expression was selected for large scale expression. 
2.19.3. Expression of GST–XIAP recombinant protein 
A volume of 100 µl of the glycerol stock with the highest expressing clone of E. coli BL21 
(DE3) pLysS cells (Section 2.16.6) was used to inoculate 100 ml Luria broth containing 100 
µg/ml ampicillin. Cells were incubated at 37 °C for 16 hours whilst shaking at 170 rpm. A 
further 900 ml Luria broth containing 100 µg/ml ampicillin was added to the primary culture 
and cells were incubated at 37 °C until OD600 reached between 0.4 and 0.6. Expression of 
recombinant protein was induced by the addition of IPTG to a final concentration of 0.2 mM 
and cells were incubated at 25 °C for 16 hours. 
Cultures were transferred to 250 ml propylene tubes and harvested by centrifugation at 
6000×g at 4 °C for 10 minutes and pellets were stored at –20 °C. 
2.19.4. Cell extract preparation and protein purification as per BugBuster® GST–Bind 
Purification Kit 
Purification of recombinant GST–XIAPS was carried out with the use of Novagen’s 
BugBuster® GST–Bind Purification Kit according to the manufacturer’s guide. 
Once thawed the pellets were re–suspended in 4 ml 1X GST Bind/Wash Buffer per 100 ml 
culture. The sample was sonicated while on ice. The lysate was centrifuged at 10 000×g for 
20 minutes. The post–centrifugation supernatant was filtered through 0.45 micron filters. 
GST–Bind resin was mixed gently by inversion until the resin was completely suspended. A 
volume of 2.5 ml of slurry was transferred to the column and the resin was allowed to settle. 
When the level of storage buffer, containing 20 % ethanol, dropped to the top of the column 
bed the resin was washed with 12.5 ml 1X GST Bind/Wash Buffer. The GST Bind/Wash 
Buffer was allowed to drain to the top of the column bed before the prepared extract was 
loaded. The prepared extract was loaded and the flow through fraction was collected and 
stored at 4 °C. The column was washed with 25 ml 1X GST Bind/Wash buffer. The wash 
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was collected and stored at 4 °C. The protein was eluted with 7.5 ml 1X GST Elution Buffer. 
The eluted fractions were collected and stored at 4 °C. The flow through, wash and eluted 
fractions were analysed for the presence of the targeted protein via 1D SDS PAGE gel 
(Section 2.21). 
 
2.20. Protein extraction from cultured human cancerous cells 
Various cell lines (A5495, H157, HepG2, HeLa, HT29, KMST and MCF7) were cultured 
until confluency. The media was decanted and cells were washed with 1X PBS. Protein 
extraction was carried out with the use of CytoBuster™ Protein Extraction Reagent 
(Novagen) according to the manufacturer’s guide. The recommended amount of 
CytoBuster™ was added and the cells were placed on a shaker for 5 minutes. Following 
incubation, the cells were scrapped off in the CytoBuster™ reagent and placed in a 1.5 ml 
tube. Cells were centrifuged at 16 000×g for 5 minutes at 4 °C. The supernatant containing 
the proteins were removed and stored at –80 °C. 
 
2.21. One Dimensional SDS Polyacrylamide Gel Electrophoresis 
2.21.1 Gel preparation 
Proteins were analysed on one dimensional (1D) SDS polyacrylamide gels (PAGE). Glass 
plates and apparatus (Bio–Rad) used were first cleaned with a soapy wash followed by 70% 
ethanol to ensure they were free of acrylamide. A 12 % separating gel solution was prepared 
(Table 2.7). To the separating gel solution, 20 µl TEMED was added and the solution was 
poured between the gel plates. The separating gel solution was overlaid with 1 ml 
isopropanol. 
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Table 2.7: Stock Solutions for the 12 % Separating Gel Solution 
Reagent Volume 
Separating Buffer (1.5 M Tris–HCl, pH 
8.8) 
2.5 ml 
40 % Acrylamide–Bis (37:5:1) 3 ml 
10 % SDS 0.1 ml 
10 % APS 0.2 ml 
Distilled Water 4.2 ml 
TEMED 0.02 ml 
TOTAL VOLUME 10.02 ml 
 
The stacking gel solution was prepared (Table 2.8). Once the separating solution was 
solidified the isopropanol was poured off and the gel was rinsed thoroughly with distilled 
water. The staking gel solution was poured above the separating gel, and a 10–well Bio–Rad 
comb was inserted immediately into the stacking gel. The gel was allowed to solidify for 10 
to 15 minutes. Once solidified, the comb was removed and the gel was set–up in a Bio–Rad 
gel electrophoresis tank. The tank was filled with 1X SDS running buffer and was pre–run at 
120 V for 10 to 15 minutes to remove any SDS or liquid acrylamide from the gel wells.  
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Table 2.8: Stock solution for the 5 % Stacking Gel Solution 
Reagent Volume 
Separating Buffer (0.5 M Tris–HCl, pH 
6.8) 
0.5 ml 
40 % Acrylamide–Bis (37:5:1) 0.63 ml 
10 % SDS 0.05 ml 
10 % APS 0.05 ml 
Distilled Water 3.77 ml 
TEMED 0.01 ml 
TOTAL VOLUME 5.01 ml 
 
2.21.2. Sample Preparation and Gel Loading 
In a 1.5 ml eppendorf tube, 10 µl of the protein sample was mixed with 10 µl of 2X sample 
buffer. Samples were boiled at 95 °C for five minutes followed by centrifugation at 14 000 
rpm in a benchtop Eppendorf centrifuge for 10 minutes at 4 °C. The protein molecular 
marker was boiled for 5 minutes at 95 °C. The samples were loaded onto the polyacrylamide 
gel and were electrophoresed at 100 V until the Coomassie dye front reached the bottom of 
the gel. 
2.21.3. Gel staining 
The gel was removed from the gel plates and stained in pre–warmed Coomassie stain for 20 
minutes on a shaker. The staining solution was removed and the gel was destained for 1 hour 
while shaking in destaining solution.  
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2.22. Analysis of XIAP expression by western blot 
2.22.1. Blot transfer of proteins onto PVDF membrane 
Proteins were electrophoresed on a 1D SDS PAGE (Section 2.21). After electrophoresis 
proteins were transferred onto BioTrace™’s PVDF membrane by blot transfer. The transfer 
took place in a tank and interchangeable lid with the vertical electrophoresis unit for 90 
minutes at 110 V. The temperature was kept at 2 to 8 °C.  
2.22.2. Analysis of XIAP expression 
The membrane was blocked in TBS–Tween containing 5 % milk for an hour at room 
temperature. The membrane was washed thrice in TBS–Tween while shaking at room 
temperature for five minutes. The membrane was incubated in XIAP monoclonal antibody at 
a dilution of 1:5000 in TBS–Tween containing 3% BSA while shaking at 4 °C overnight. The 
membrane was washed in TBS–Tween containing 5% milk powder while shaking at room 
temperature for five minutes. The membrane was washed twice in TBS–Tween while shaking 
at room temperature for five minutes. Thereafter, the membrane was incubated in goat anti–
mouse IgG–HRP antibody at a dilution of 1:5000 in TBS–Tween containing 3% BSA while 
shaking for 45 minutes at room temperature. The membrane was washed in TBS–Tween 
containing 5% milk powder while shaking at room temperature for five minutes. The 
membrane was washed twice in TBS–Tween while shaking at room temperature for five 
minutes. The membrane was incubated with 2 ml Thermo Scientific’s SuperSignal® West 
Pico Chemiluminescent Substrate for five minutes in the dark. 
2.22.3. Exposure of membrane 
The UVP BioSpectrum® Imaging System and Vision Works™ LS Image Acquisition and 
Analysis Software was used to visualize and capture images of the membrane. 
 
2.23. Densitometric analysis of western blot 
ImageJ densitometry software (Version 1.46r, National Institutes of Health, Bethesda, MD) 
was used for gel band quantitative densitometric analysis. Bands were quantified based on 
their relevant intensities. 
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2.24. Evaluating the interaction between the recombinant GST–XIAP protein and 
embelin 
The recombinant GST–XIAP protein was quantified to having a concentration of 0.006 µM. 
To evaluate the binding between recombinant GST–XIAP protein and embelin using the 
MicroCal™ iTC200 System, embelin had to be 10 – 15 more concentrated. Therefore, 200 nM 
embelin was prepared in 5 mM phosphate buffer containing 0.15% DMSO. A total of 18 
injections of 200 nM embelin were introduced by pipette into the cell unit containing 
recombinant GST–XIAP protein. Origin® scientific plotting software was used to analyse the 
calorimetric data generated.  
As a negative control, a total of 18 injections of 5 µM EDTA was introduced by pipette into 
the cell unit containing 0.5 µM calcium. Analysis was possible using the Origin® scientific 
plotting software. 
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3.1. Evaluating the expression levels of XIAP in human cancer cells 
3.1.1. Introduction 
XIAP is the best and thoroughly characterized human IAP (Holcik et al., 2003; Fischer and 
Schulze–Osthoff, 20052). It consists of three BIR regions as well as a RING domain (Holcik 
et al., 2003; Schimmer, 2004). Tamm and colleagues have previously reported that XIAP was 
widely expressed in mammalian tumour cell lines (Tamm et al., 2000). The aim of this 
section was to determine XIAP expression levels among various mammalian cancer cell lines 
that were available in our laboratory. This was later used to identify cancer lines where XIAP 
was expressed at both low and high levels. Identified low and high XIAP expressing cancer 
cells were treated with embelin and embelin conjugates to investigate embelin’s inhibitory 
effect on XIAP. 
3.1.2. Western blot analysis of XIAP expression in various human cancer cell lines 
The panel of human cancer cell lines that were investigated included A5495, H157, HepG2, 
HeLa, HT29 as well as MCF7. Proteins were extracted as described in Section 2.20 to 
evaluate XIAP expression using the XIAP monoclonal antibody. 
Samples were analysed on a 1D SDS PAGE gel prior to western blot analysis. According to 
Figure 3.1 a distinct band was visible in all the available cell lines. These bands had a size of 
approximately 70 kDa. Non–specific bands were detected as their sizes were smaller when 
compared to the size of the XIAP protein. It may be deduced, from Figure 3.1, that 
successful protein extraction using CytoBuster™ Protein Extraction Reagent was achieved. 
Confirmation of this 70 kDa band to be XIAP was achieved by Western Blot Analysis.  
The extracted protein samples were used for Western Blot analysis to determine XIAP 
expression. Figure 3.2 shows XIAP expression in various mammalian cancer cell lines 
available. High XIAP expression was observed in H157 and MCF7 whereas low XIAP 
expression was observed in A5495, HepG2, HeLa and HT29 mammalian cancer cell lines.  
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Figure 3.1: 1D SDS polyacrylamide gel electrophoresis of proteins extracted from 
available mammalian cancer cells. Proteins were extracted from confluent cells by using 
CytoBuster™ Protein Extraction Reagent.  
 
 
XIAP 
Actin 
Figure 3.2: Western Blot of XIAP expression in mammalian cancer cells. The XIAP 
monoclonal antibody was used to determine the levels of XIAP expression in various 
mammalian cancer cells available, Actin antibody was used to verify equal loading. 
 
The results obtained from western blot analysis were quantified using the ImageJ Software 
(www.imagej.nih.gov/ij/). The densitometry data for the band intensity for expression of the 
XIAP protein were used to construct a bar graph. Figure 3.3 shows high density values for 
the XIAP protein in cells lines H157, MCF7, with A5495 displaying the most intensity. Low 
density values were detected in HeLa, HT29, with HepG2 displaying the least intensity.  
 
50 kDa 
70 kDa XIAP  
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Figure 3.3: Densitometry data for XIAP Protein Expression. XIAP protein expression 
levels were quantified for the respective cancer cell lines available in the laboratory. 
Quantification was possible with the ImageJ software. 
 
3.2. Evaluating the apoptotic effects of ceramide as an apoptotic inducer 
3.2.1. Introduction 
Inhibitors of apoptosis proteins (IAPs) are a family of anti–apoptotic proteins where they 
mainly function in regulating caspase activity. IAPs regulate apoptosis directly by inhibiting 
caspase 3 and/ caspase 7 thereby preventing the main execution phase of apoptosis. IAPs also 
prevent the intrinsic apoptotic pathway by caspase 9 inhibition (Riedl et al., 2001). 
The X–chromosome linked inhibitor of apoptosis protein (XIAP) is the best (Schimmer, 
2004) and most thoroughly characterized human IAP (Fischer and Schulze–Osthoff, 20052). 
XIAP overexpression protects cells from different apoptotic triggers and may lead to cancer 
(Holcik et al., 2003). 
Embelin is a cell–permeable, small molecular weight inhibitor of XIAP which was identified 
via computational screening (Nikolovska–Coleska et al., 20042). Embelin or 2,5–dihydroxy–
3–undecyl–1,4–benzoquinone was isolated from the plant Embelia ribes (Siegelin et al., 
2009) which has been used to treat inflammatory disease as well as fever for many years 
(Pathan and Bhandari, 2011). Embelin targets XIAP’s BIR3 domain thereby blocking the 
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inhibitory effect of XIAP on caspases, and consequently promotes apoptosis (Nikolovska–
Coleska et al., 2004
2
).  
Current cancer treatment options are distributed non–specifically in the body. As they affect 
both the cancerous and normal cells, the achievable dose within the tumour is limited. This 
results in suboptimal treatment due to excessive toxicities (Cho et al., 2008).  
The use of nanoparticles for medical purposes is based on their quantum properties, their 
ability to absorb and carry other compounds and mainly their surface–to–mass ratio which is 
much larger when compared to other nanoparticles. The surface of nanoparticles is large and 
functional in that they able to bind, absorb and carry compounds such as drugs, probes and 
proteins (de Jong and Borm, 2008). 
As XIAP is inhibited by embelin (Nikolovska–Coleska et al., 20041; Nikolovska–Coleska et 
al., 2004
2
), the objective of this section was to evaluate the inhibitory effect of embelin on 
XIAP when embelin was conjugated to gold nanoparticles (AuNP–E) as well as conjugation 
of embelin and a specific cancer targeting peptide to gold nanoparticles (AuNP–P–E). MCF7 
and HepG2 cells were cultured and treated as described in Section 2.5.  
3.2.2. Characterization of conjugated gold nanoparticles  
Gold nanoparticles (sized 14 nm) were synthesized and supplied by Dr. Franklin Keter 
(Mintek). Figure 3.4 indicates a schematic representation of an unconjugated gold 
nanoparticle when compared to gold nanoparticles conjugated with embelin (AuNP–E) and 
gold nanoparticles biconjugated with embelin and the cancer targeting peptide LTVSPWY 
(AuNP–P–E).  
Gold nanoparticles (AuNPs) were conjugated with embelin (AuNP–E) as well as a cancer 
targeting peptide LTVSPWY (Shahidi and Sioud, 2003) and embelin (AuNP–P–E) and 
supplied by Dr. Franklin Keter (Mintek). Table 3.1 shows the optical properties for AuNP-E 
and AuNP–P–E. The data comprised of UV Vis spectra (Figure 3.5) and TEM (Figure 3.6) 
were generated by Dr. Keter post synthesis. 
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Figure 3.4 : A schematic representation of gold nanoparticles before and after 
conjugation. Panel (a) shows an unconjugated nanoparticle. Panel (b) shows gold 
nanoparticle conjugated with embelin (AuNP–E). Panel (c) shows a gold nanoparticle 
biconjugated with embelin and the cancer targeting peptide LTVSPWY (AuNP–P–E). 
 
Table 3.1: Optical Properties of AuNP–E and AuNP–P–E 
Features AuNP–E AuNP–P–E 
UV Absorbance 519 nm 524 nm 
Concentration (OD) 2.5094 1 
½ OD 563 nm 575 nm 
Citrate Concentration 1.14% 1.14% 
 
    
Figure 3.5 : UV Vis spectra for (a) AuNP–E and (b) AuNP–P–E. A single peak is 
visualized in both spectra at a wavelength of 519 nm and 524 nm respectively. The 
absorbance of embelin–AuNP is approximately 2.5 whereas the absorbance of the peptide–
embelin–AuNP is approximately 1.0. 
  AuNP    AuNP–E   
Embelin  
  AuNP-P–E   
Embelin  
Cancer Targeting 
Peptide: LTVSPWY  
a) c) b) 
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Figure 3.6: TEM data for (a) AuNP–E and (b) AuNP–P–E. The magnification for the 
embelin–AuNP and peptide–embelin–AuNP was at 100 nm and 20 nm respectively. 
Figure 3.5 (a) and (b) shows the absorbance spectra for AuNP–E and AuNP–E–P, 
respectively. The optical absorption spectra occurred in the range of 300 – 800 nm for AuNP–
E and 350 – 800 nm for AuNP–E–P. The AuNP–E had an absorbance of 2.5 corresponding to 
a wavelength of 519 nm (Table 3.1). The AuNP–E–P had an absorbance of 1.0 corresponding 
to a wavelength of 524 nm (Table 3.1). Figure 3.6 it was observed that the conjugated 
nanoparticles were distributed uniformly and resembled a spherical shape.  
3.2.3. Morphological changes in MCF7 and HepG2 cancer cells upon treatment 
MCF7 and HepG2 cancer cells were cultured and treated as described in Section 2.5. Figure 
3.7 and Figure 3.8 shows the changes in morphology for the HepG2 and MCF7 cells 
respectively post 24 hour treatment.  
Post treatments both HepG2 and MCF7 cells treated with embelin, AuNP–E and AuNP–P–E 
resembled the untreated cells. Therefore, no morphological differences were detected when 
compared to the untreated controls. It was also observed that the treatments involving 
ceramide, cells shrunk, rounded up and there were cells that detached from the surface of the 
well. It may be deduced that ceramide was responsible for the changes in morphology. 
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Figure 3.7: Morphology of HepG2 liver cancer cells treated with embelin, AuNP–E orAuNP–P–E as well as co–treatments with ceramide. 
Morphological differences, observed using a Nikon TMS light microscope with a 20X magnification, included shrinkage of cells (black arrows) as well 
as rounded detached cells (red arrows). 
Untreated Embelin (50 µM) AuNP (5 nM) AuNP–E (5 nM) AuNP–P–E (5 nM) 
Ceramide (50 µM) 
  
 
 
 
 
61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8:  Morphology of MCF7 breast cancer cells treated with embelin, AuNP–E or AuNP–P–E as well as co–treatments with ceramide. 
Morphological differences, observed using a Nikon TMS light microscope with a 20X magnification, included shrinkage of cells (black arrows) as well as 
rounded detached cells (red arrows). 
Untreated Embelin (50 µM) AuNP (5 nM) AuNP–E (5 nM) AuNP–P–E (5 nM) 
  
Ceramide (50 µM) 
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3.2.4. Induction of apoptosis on MCF7 and HepG2 cancer cells as a result of the 
treatment options 
Apoptosis was assayed by flow cytometry using the FACScan (BD Biosciences) flow 
cytometer (Section 2.5). Cells were harvested and stained with APOPercentage™ dye. This 
assay is used for detection and measurement to monitor the occurrence of apoptosis in 
mammalian cells where cells undergoing apoptosis are stained. The data obtained was used to 
construct bar graphs depicting the percentage of cell death (Figure 3.9). 
The percentage of apoptosis for the respective treatments showed the same trend for both the 
HepG2 and MCF7 cancer cell lines. Individual ceramide treatments yielded percentages of 
apoptosis close to 60%. It was observed that co–treatments comprised of ceramide and 
embelin conjugates yielded percentages of apoptosis above 50%. The highest percentage of 
apoptosis arose from the AuNP–E + ceramide treatment. This was followed by AuNP–P–E + 
ceramide and embelin + ceramide yielded the lowest percentage of apoptosis of the trio. 
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Figure 3.9: Indications of apoptosis of (a) HepG2 and (b) MCF7 cancer cells as a result of the various treatment options. Post 24 hour treatments, 
cells were stained with APOPercenrage™ dye. Cells that were positive for apoptosis were quantified by flow cytometry using the FACScan. Data was 
obtained in triplicate and were used to construct histograms for HepG2 and MCF7 cancer cells (mean ± SD; n = 3).  
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3.2.5. Evaluating the cellular uptake of AuNP–E and AuNP–P–E 
MCF7 and HepG2 cancer cells were treated for 24 hours with AuNP–E and AuNP–P–E. To 
evaluate the uptake of the gold nanoparticles two techniques were used, namely, Inductively 
Coupled Plasma–Optical Emission Spectrometry (ICP–OES) and Transmission Electron 
Microscopy (TEM).  
3.2.5.1. Inductively Coupled Plasma–Optical Emission Spectrometry 
MCF7 and HepG2 cancer cells cultured and treated as described in Section 2.6 for ICP–OES 
Analysis. The objective of ICP–OES was to determine the concentration (Figure 3.10 (a)) 
and percentage of gold taken up (Figure 3.11 (b)) by the treated cancer cells. This was 
achieved using the Varian 1600 ES instrument and the ICP expert 11 software.  
When comparing the concentration of gold present post treatment, for both MCF7 and 
HepG2 cancer cells, more gold was present in the AuNP–P–E treatment when compared to 
the AuNP–E treatment. Hence, the percentage of gold detected was higher in the AuNP–P–E 
treatment (Figure3.10 (a) and Figure 3.11 (b)). 
In both treatments, the concentration of gold present in the cells present indicates that 
embelin was taken up by the cancerous cell. However, an increased in gold concentration 
present post AuNP–P–E treatment suggests that targeted delivery of embelin to the XIAP site 
was achieved by the presence of the targeting peptide.  
3.2.5.2. Transmission Electron Microscopy  
MCF7 breast and HepG2 liver cancer cells were cultured and treated as described in Section 
2.7. Post 24 hour treatments cells were harvested and prepared for TEM Analysis. Analysis 
was performed by the National Health Laboratory Services (Tygerberg Hospital, Cape 
Town). The objective of TEM was to visualize the uptake of gold in the treated HepG2 
(Figure 3.10) and MCF7 (Figure 3.11) cancer cells. This was achieved using the JEOL 
JEM–1011 Electron Microscope instrument and the cis analysis program iTEM imaging 
software. 
Images of untreated HepG2 and MCF7 cells were captured were the bar was represented at 
20 µm. Cells treated with 5 nM AuNP as well as co–treated with 5nM AuNP–P–E + 50 µM 
ceramide had images captured at a magnification of 10 µm. The lower magnification 
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indicated the presence of the AuNPs within the organelles (inserts: the bar was represented at 
2 µm).  
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Figure 3.10: Evaluating the presence of gold in MCF7 breast and HepG2 liver cancer cells treated with AuNP–E and AuNP–P–E. Post 24 hour 
treatment, cells were prepared for ICP analysis. The average of the data obtained were used to determine the (a) concentration and (b) percentage of gold 
present in the treated cells (mean ± SD; n = 2). 
It was observed that the concentration of gold was higher in the AuNP–P–E when compared to AuNP–E (Figure 3.10 (a)). The percentage of 
gold taken up post treatments was also higher in the AuNP–P–E when compared to AuNP–E (Figure 3.10 (b)).  
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Figure 3.11: Evaluating the uptake of AuNP–E and AuNP–P–E in HepG2 and MCF7 cells. Post 24 hour treatment, cells were prepared for TEM 
analysis. Images of HepG2 and MCF7 untreated cells were captured where the bar was represented at 20 µm. Images of cells treated with AuNPs were 
captured where the bar was represented at 10 µm. The inserts were taken at 5 µm to indicate the uptake of the AuNPs. 
HepG2: Untreated 
MCF7: Untreated 
HepG2: 5 nM AuNP HepG2: 5 nM AuNP–P–E + 50 µM Ceramide 
MCF7: 5 nM AuNP MCF7: 5 nM AuNP–P–E + 50 µM Ceramide 
 
 
 
 
68 
 
3.3. Cloning of XIAP into a His–tagged Expression Vector System 
3.3.1. Introduction 
To evaluate the binding of embelin, AuNP–E and AuNP–P–E to XIAP, it was necessary to 
express and purify recombinant XIAP protein. Therefore the objective of this section was to 
express and purify recombinant human XIAP protein using the pET28a expression vector. 
3.3.2. The isolation of total RNA from MCF7 breast cancer cells 
As shown in Section 3.1.2 Figure 3.1 XIAP was over expressed in MC7 breast cancer cells. 
MCF7 cells were cultured in 25 cm
2
 flasks at 5% CO2 and 37 °C until confluent (Section 
2.3). Total RNA was isolated using Machery–Nagel’s NucleoSpin® Tri Prep Kit (Section 
2.9). The RNA was electrophoresed on a 1% agarose gel (Figure 3.12). Two major bands 
representing the two RNA subunits (i.e. 28 S and 18 S) were observed on Figure 3.12. Both 
the 28 S and 18 S subunits remained intact. A third band was present and less visible than the 
other bands. This band represents the 5 S subunit. 
 
 
 
Figure 3.12: Total RNA isolated from MCF7 mammalian breast cancer cells. RNA was 
isolated using the NucleoSpin® TriPrep Kit. The first lane is the DNA marker and the second 
lane is the total RNA. The three red arrows on the right indicate RNA subunits (28 S, 18 S 
and 5 S) present in the total RNA sample.  
3.3.3. PCR amplification of XIAP 
The total RNA sample was used to synthesize cDNA using the First Strand cDNA Synthesis 
Kit for RT–PCR (AMV) as described in Section 2.9. The resulting cDNA was used to PCR 
28 S 
18 S 
1 000 bp 
5 S 
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amplify XIAP’s coding region (as described in Section 2.12) using XIAP specific primers as 
described in Section 2.11.  
The PCR amplified product was electrophoresed on a 1% agarose gel (Figure 3.13) and the 
gel image was captured (Section 2.9.1). The PCR amplification indicates a PCR product for 
the XIAP gene at approximately the expected size of 1494 bp. The PCR amplified product 
was excised and gel purified (Section 2.14). The purified product was ligated into the 
pGEM–T Easy Vector System. 
 
 
 
Figure 3.13: PCR amplification of XIAP with the use of gene specific primers. The first 
lane of the agarose gel shows the 1kb DNA marker, the second the negative control (no 
cDNA present) and the third lane the PCR product generated with MCF7 cDNA as the 
template. 
3.3.4. Sub–cloning of XIAP into pGEM–T Easy Vector 
The amplified XIAP PCR product purified using the NucleoSpin® Extract II PCR Clean–Up 
Gel Extraction Kit as described in Section 2.14. The purified DNA was used in a sub–cloning 
experiment ligating the XIAP PCR product into the pGEM–T Easy vector. The ratio of 
insert:vector used was 3:1 (Table 2.5) and the ligation reaction was used to transform E. coli 
competent cells as described in Section 2.15.3. 
3.3.5. Colony PCR screening of XIAP positive clones 
The resulting pGEM–XIAP transformed colonies were screened for the presence of XIAP by 
colony PCR using XIAP specific primers (Section 2.15.4). The PCR products were 
XIAP 1500 bp 
500 bp 
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electrophoresed on a 1% agarose gel (Figure 3.14) and the image was captured. The 
amplified products were at the expected size of 1494 bp for XIAP.  
 
 
 
Figure 3.14: Colony PCR screening for XIAP positive clones. Ten clones (numbered 1 – 
10) were screened. The last lane shows the negative control where no template DNA was 
added to the PCR reaction. 
3.3.6. Sequence analysis of XIAP positive clones  
Clones that were positive for XIAP were cultured LB–ampicillin and 20% v/v glycerol stocks 
were prepared (Section 2.15.6). These clones were used to streak LB–ampicillin agar plates. 
Agar plates that contained positive clones were sent to Inqaba Biotec for DNA sequencing 
analysis. Two clones per plate were selected and sequenced in the forward and reverse 
orientation with the use of M13 sequencing primers. The DNA sequences received from 
Inqaba Biotec were analysed using BLAST (Altschul et al., 1990) analysis. The BLAST 
analysis (Figure 3.15) for the XAIP clone 3 showed a 99% identity when compared to the 
original XIAP sequence. From the sequencing data three single mutations were observed. 
1500 bp 
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Figure 3.15: BLAST sequence analysis of a positive clone 3 for XIAP. The red boxes 
indicate the three mutations. The database utilized two query fields. The Query field 
indicates the DNA sequence of the clone of interest whereas the Subject field indicates the 
DNA sequence for the original XIAP gene to which the clone of interest was compared. 
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The DNA sequences received from Inqaba Biotec were translated into protein sequences 
using ExPASY (http://www.expasy.org). A pairwise sequence alignment of the original 
XIAP gene and pET28a–XIAP (Figure 3.16) was generated. Two mutations were observed 
in the translated sequence. Should the mutations have resulted in an amino acid change, the 
folding formation of XIAP may be affected. 
 
Figure 3.16: Pairwise protein sequence of the translated DNA sequence obtained for a 
positive XIAP clone and XIAP protein sequence. The translated sequences were 
compared to the protein sequence of human XIAP. The red boxes indicate mutations. 
3.3.7. XIAP release from pGEM–XIAP by restriction digestion 
In order for the ligation of the XIAP fragment into pET28a (Section 2.16), pGEM–XIAP 
plasmid DNA was digested with restriction enzymes (Xho1 and Nde1) to release the XIAP 
insert (Section 2.15.7). 
Clone 3 of pGEM–XIAP was selected for sequencing. The sequences were analysed prior to 
plasmid DNA preparation using Promega’s Wizard® Plus SV Miniprep DNA Purification 
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System (Section 2.15.6). The digested DNA was electrophoresed on a 1% agarose gel and 
the image was captured using the Kodak Digital Science 1D System (Figure 3.17). 
The undigested plasmid (Figure 3.17, lane 2) indicates three bands which represents the three 
forms of plasmid namely the supercoiled, nicked and linear. The digested plasmid (Figure 
3.17, lane 3) was achieved using restriction enzymes Xho1 and Nde1. Three bands can be 
visualized where the first band indicates linearized vector, the second band indicates the 
digested vector and the third band indicates the XIAP insert which was released successfully. 
 
 
 
 
Figure 3.17: Restriction digestion of pGEM–XIAP. Plasmid DNA was digested with 
Xho1 and Nde1. The first lane of the agarose gel shows the DNA marker, the second the 
undigested pGEM–XIAP plasmid DNA and the third lane the pGEM–XIAP plasmid DNA. 
Indicated by the arrows are the pGEM–T Easy vector and the XIAP insert.  
 
3.3.8 Preparation of the pET28a expression vector for DNA ligation 
For ligation of the XIAP fragment into pET28a expression vector (Section 2.16.3), both the 
pGEM–XIAP and pET28a vector were digested with restriction enzymes Xho1 and Nde1 as 
described in Section 2.16.2. As pGEM–XIAP was digested and resulted in successful release 
of XIAP the pET28a vector was digested with enzymes Xho1 and Nde1 (Section 2.16.2). The 
digested pET28a vector was electrophoresed on a 1% agarose gel and the image was captured 
using the Kodak Digital Science 1D System (Section 2.9.1). The undigested plasmid (Figure 
3.17, lane 2) indicates three bands which represents the three forms of plasmid namely the 
1500 bp 
Vector 
XIAP Insert 
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supercoiled, nicked and linear. The digested pET28a vector produced a single band 
representing an intact and linear plasmid.  
 
 
 
Figure 3.18: Restriction digestion of the pET28a expression vector. The first lane of the 
agarose gel shows the DNA marker, the second the uncut pET28a vector and the third lane 
the pET28a vector digested with Xho1 and Nde1. Indicated by the arrow is the linearized 
pET28a vector. 
The linearized pET28a vector was gel purified as described in Section 2.14. XIAP from 
pGEM–XIAP was ligated into the linearlized pET28a Expression Vector. The ratio of 
insert:vector used was 3:1 (Table 2.6) and the ligation reaction was used to transform E. coli 
competent cells (Section 2.16.4). 
3.3.9 Screening of XIAP positive clones by colony PCR 
The resulting transformed colonies were screened for the presence of XIAP by colony PCR 
(Figure 3.19). Gene specific primers were used to detect the presence of the insert (Section 
2.11). The PCR products were electrophoresed on a 1% agarose gel and the image was 
captured using the Kodak Digital Science 1D System (Section 2.9.1). The amplified products 
were at the expected size of 1494 bp for XIAP. 
 
 
 
 
1500 bp 
Linearized pET28a Vector 
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Figure 3.19: Colony PCR screen for XIAP positive clones. Ten clones (numbered 1 – 
10) were screened. The second lane shows the negative control where water was used as the 
template in the PCR reaction. 
 
3.4. Affinity purification of recombinant His–XIAP  
3.4.1. Introduction 
Upon successful ligation of XIAP into the linearlized pET28a vector, the objective of this 
section was to express XIAP in E. coli and purify the protein using the Ni–NTA His–Bind® 
Resin since the protein will be expressed as a His–tagged fusion protein.  
3.4.2. Screening for the expression XIAP 
The colony PCR amplification results in Figure 3.19 indicated the presence of XIAP in all 
the clones selected. From this data, clone 4 was selected to screen for XIAP as described in 
Section 2.15.6. 
XIAP has a size of approximately 57 kDa. Therefore, His–XIAP was expected to be 
visualized at approximately 63 kDa. Also, it was expected to distinguish XIAP expression 
between the uninduced and induced samples. According to Figure 3.20 XIAP expression 
levels were similar with the exception of clone 3. Addition of IPTG resulted in an increased 
expression of XIAP when compared to the uninduced sample. 
 
 
1500 bp 
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Clone 1 Clone 2 Clone 3 Clone 4  
 
 
 
Figure 3.20: Expression screen for His–XIAP protein. Four colonies (numbered clone 1 
– 4) were selected. Induction was achieved with 1 mM IPTG.  
3.4.3. Purification of His–XIAP recombinant protein using the Ni–NTA His–Bind® 
Resin 
From the expression screen, clone 3 was selected for recombinant purification of His–XIAP 
(Figure 3.21) with the aid of Novagen’s Ni–NTA His–Bind® Resin supplied by Merck 
(Section 2.18.1).  
When comparing the concentration of protein present in the lysate sample to the eluted 
samples, it was observed that very little protein was eluted. Purification of the XIAP–His 
protein was attempted using the HIS–Select® Nickel Affinity Gel to purify more of the 
recombinant His–XIAP protein and at increased efficiency when using the Novagen’s Ni–
NTA His–Bind® Resin. This purification experiment was unsuccessful as protein was 
present in the lysate sample but absent in the eluted samples (data not shown). 
 
 
 
 
52 kDa 
72 kDa 
His–XIAP  
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Figure 3.21: Purification of the His–XIAP protein using Ni–NTA His–Bind® Resin. 
Lane 1 shows the protein marker, lane 2 shows the lysate, lane 3 shows the flow through, 
lanes 4 and 5 the two washes and lanes 6 to 10 the eluted His–XIAP protein. 
 
3.5. Affinity purification for recombinant GST–XIAP 
3.5.1. Introduction 
The objective of this section was to express and purify the recombinant XIAP protein. 
Recombinant XIAP was required to evaluate its binding to (i) embelin post conjugation of 
embelin to gold nanoparticles and (ii) biconjugation of embelin and specific cancer targeting 
peptide to gold nanoparticles. Expression and purification of recombinant XIAP was carried 
out as described in Section.17. As purification of His–XIAP was unsuccessful, the pGEX–
XIAP construct was purchased from Addgene. The purchased construct was used for 
expression and purification of GST–XIAP protein as described in Section 2.19.  
3.5.2 Expression screen of GST–XIAP  
Upon receiving the construct, the step involved screening for XIAP. This was achieved as 
described in Sections 2.19.1 up to and including Section 2.19.3. Suspected positive clones 
were selected to screen for the presence of GST–XIAP (Figure 3.22). 
XIAP has a size of approximately 57 kDa. Therefore, GST–XIAP was expected to be 
visualized at approximately 83 kDa. It was expected to distinguish XIAP expression between 
His–XIAP  
50 kDa 
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the uninduced and induced samples. According to Figure 3.22 XIAP expression levels were 
higher in the induced samples when compared to the uninduced samples. Expression was 
increased due to the addition of 0.2 mM IPTG. Of the 4 clones selected, clone 3’s induced 
sample showed a higher level of XIAP expression.  
 
 
 
 
Figure 3.22: Expression screen for GST–XIAP protein. Four colonies (numbered colony 
1 – 4) were selected. Induced samples were clearly distinguished from uninduced samples. 
Induction was achieved with 0.2 mM IPTG.  
3.5.3. Sequence analysis of GST–XIAP 
From the expression screen (Figure 3.22) clone 3 was selected for large scale purification 
after sequence analysis. Glycerol stocks were used to streak LB–ampicillin agar plates which 
were sent to Inqaba Biotec for sequencing. Sequence analysis was carried out as described in 
Section 3.3.6. However, pGEX specific sequencing primers were used. A pairwise sequence 
alignment of the translated DNA sequence for XIAP (Figure 3.23) was generated.  
Sequencing data obtained from Inqaba Biotec was translated into protein sequences using 
ExPASY. A pairwise sequence alignment was generated of the original XIAP gene and GST–
XIAP. From Figure 3.23 no mutations were observed in the translated sequences. 
50 kDa 
GST–XIAP  85 kDa 
Clone 1 Clone 2 Clone 3 Clone 4 
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Figure 3.23: Pairwise protein sequence of the translated DNA sequence for a positive 
clone of XIAP from the pGEX–4T–2 vector. The translated sequences were compared to 
the protein sequence of human XIAP.  
3.5.4 Purification of GST–XIAP using BugBuster® GST–Bind Purification kit 
From the expression screening (Figure 3.22), clone 3 was selected for sequencing. Post 
sequence analysis, cell extraction preparation and purification of GST–XIAP (Section 2.19.4) 
was carried out using Novagen’s BugBuster® GST–Bind Purification Kit supplied by Merck 
(Figure 3.24). 
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Figure 3.24: Purification of the GST–XIAP protein using the BugBuster® GST–Bind 
Purification kit. Lane 1 shows the protein marker, lane 2 shows the pellet, lane 3 shoes the 
lysate, lane 4 shows the flow through, lane 5 shows the first wash sample, lanes 6 to 8 
shows the eluted GST–XIAP protein and lane 9 shows the second wash sample. 
 
3.6. Evaluating the interaction between the recombinant GST–XIAP protein and 
embelin and embelin conjugated nanoparticles by Isothermal Titration Calorimetry 
(ITC) 
3.6.1. Introduction 
Binding affinities and stoichiometries between proteins and nanoparticles are highly relevant 
in understanding protein–nanoparticle interactions and their biological consequences. The 
rate at which the respective protein binds to or dissociates from the nanoparticle, determines 
the interaction with receptors and hence its biological effects (Cerdervall et al., 2007). The 
objective of this section is to evaluate the thermodynamics of recombinant GST–XIAP and 
embelin–conjugated gold nanoparticles using Isothermal Titration Calorimetry (ITC). 
3.6.2. ITC analysis 
The binding interaction between the recombinant GST–XIAP protein and embelin was 
evaluated by ITC using the MicroCal™ iTC200 System and analysed using Origin® scientific 
72 kDa GST–XIAP  
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plotting software. As a negative control, a binding experiment was carried out between 
calcium and EDTA.  
The control experiment consisted of calorimetric titration of 0.5 µM calcium with 5 µM 
EDTA. The experiment consisted of 18 injections of EDTA into the cell already filled with 
calcium. The injections were made over a period of 120 minutes. For each injection of EDTA 
into the cell containing calcium, Origin® takes a record and presents it graphically as shown 
in Figure 3.23 (a). Here each peak is a representation of an injection. The data is represented 
as µcal per second versus time in minutes.  
Figure 3.25 shows the raw calorimetric data obtained per injection of 5 µM EDTA into the 
calorimetric cell containing 0.5 µM calcium. A total of 18 injections of EDTA were injected 
into the calcium over a period of 60 minutes. The number of injections corresponded to 
reference points which served the foundation for the construction of the sigmoidal curve 
(Figure 3.26) which was used to obtain the thermodynamics as a result of the binding 
interactions between EDTA and calcium. 
In the experimental setup attempting to study the interaction between embelin and GST–
XIAP, 200 nM embelin was injected into the unit cell containing 6 nM recombinant GST–
XIAP protein. The injections were recorded and are represented graphically as shown in 
Figure 3.24. When comparing Figure 3.24 (a) to Figure 3.25, it was observed that the raw 
calorimetric data of Figure 3.24 (a) differed to that of Figure 3.24 in that the peaks 
representing heat interaction was present in Figure 3.24 (a) but absent in Figure 3.25. The 
raw calorimetric data from Figure 3.24 was insufficient to construct a titration plot. Hence, it 
was unable to calculate the binding constant, the heat change or entropy change.  
Figure 3.27 shows the raw calorimetric data obtained per injection of 200 nM embelin into 
the calorimetric cell containing 6 nM fused GST–XIAP recombinant protein. When 
comparing Figure 3.27 to Figure 3.25, there are no similarities to the data generated. Figure 
3.27 generated no reference points for the construction of the sigmoidal curve. Hence, it was 
unable to obtain the thermodynamics of the binding, if there existed, between embelin and the 
fused GST–XIAP recombinant protein. 
 
 
 
 
 
82 
 
         
Figure 3.25: ITC titration data describing the interaction of EDTA with calcium. Panel (a) shows the raw calorimetric data obtained during the 
injection of 5 µM EDTA into the calorimetric cell containing 0.5 µM calcium. Panel (b) shows the titration plot from the integrated raw data of the curve in 
panel (a). The solid line represents the squares which best fits the data. 
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Figure 3.26: ITC titration data describing the interaction of recombinant GST–XIAP protein and 
embelin. This indicates the raw calorimetric data obtained during the injection of 200 nM embelin into 
the calorimetric cell containing 6 nM recombinant GST–XIAP protein. Both the GST–XIAP protein and 
embelin were prepared in 5 mM sodium phosphate, buffer at pH 7.4, containing 0.15% DMSO. 
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CHAPTER 4: DISCUSSION 
XIAP is considered to be the most potent and versatile caspase inhibitor within the IAP 
family (Hui et al., 2010). XIAP blocks the induction of apoptosis by inhibiting initiator 
caspase 9 (Nikolovska–Coleska et al., 2004) and effector caspases 3 and 7 (Deveraux et al., 
1997; Mufti et al., 2007). 
Nikolovska–Coleska and colleagues over–expressed XIAP in Jurkat cells by transfecting 
these cells with a plasmid encoding the human XIAP gene. Jurkat cells that stably over–
express XIAP became resistant to apoptosis induced by etoposide when compared to 
untransfected Jurkat cells. Treatment with 2.5 µM etoposide for 72 hours resulted in 94.3% 
cell death in untransfected cells whereas only 59% of the transfected cells died. When 
increasing the concentration of etoposide to 10 µM, 85% of the transfected cells were killed. 
These results demonstrated that XIAP over–expression protected the Jurkat cells from 
etoposide–induced apoptosis and cytotoxicity (Nikolovska–Coleska et al., 20042). It can 
therefore be concluded the the over–expression of XIAP in cancer cells contributes to the 
resistance of these cells to apoptosis, which is a characteristic of cancer cells. 
Hui and colleagues therefore considered XIAP as one of the leading targets for anti–cancer 
drug development (Hui et al., 2010), since the successful inhibition of XIAP can promote the 
destruction of cancer cells through anti–cancer drug induced apoptosis. 
Embelin is a potent, non–peptidic, cell permeable small molecule inhibitor of XIAP. It has 
been shown to possess both anti–tumour and anti–inflammatory properties (Joshi et al., 2007; 
Siegelin et al., 2009). Embelin inhibits XIAP by binding to its BIR3 domain (Nikolovska–
Coleska et al., 2004
1
; Nikolovska–Coleska et al., 20042). Embelin consist of a quinone and 
hydroquinone groups on the same ring. It also has a long alkyl side chain which confers 
solubility in non–polar phase (Joshi et al., 2009). 
Although drugs such as embelin and their derivatives are promising anti–cancer agents, a 
major obstacle in the treatment of cancer is the non–specific delivery of such anti–cancer 
drugs. Therefore this study aimed at investigating the application of gold nanoparticles 
(AuNPs) for the targeted delivery of embelin to cancer cells. The main advantage of targeted 
drug delivery is to improve the therapeutic efficacy of the anti–cancer drug. Other advantages 
include the lowering of the required dose of the anti–cancer drug whilst reducing side effects 
(Papasani et al., 2012). 
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Cancer targeting peptides have been shown to specifically bind to cancer cells. The cancer 
targeting peptide consisting of the following 7 amino acids LTVSPWY was previously 
identified and shown to exhibit preferential binding to and internalization into breast cancer 
cells (Shadidi and Sioud, 2003
2
). The aim was to use this peptide to target the delivery of 
embelin into the cells using AuNPs as a drug carrier. To achieve this AuNPs were 
biconjugated with embelin and the cancer targeting peptide.  
When using nanoparticles for drug delivery, there are several challenges that can obstruct 
nanoparticles from reaching their target. For example the uptake of nanoparticles by the 
reticuloendothelial system (RES) results in nanoparticles shuttled out of circulation to the 
liver, spleen or bone marrow as well as nonspecific binding of nanoparticles to non–targeted 
or non–diseased areas. Concerns about the toxicity of nanoparticles often arise due to 
nanoparticle accumulation in the RES. Therefore, the addition of PEG to the nanoparticle 
surface, a process known as PEGylation, can reduce many of these challenges. PEG is a 
coiled polymer of repeating ethylene ether units with dynamic conformations. The addition of 
PEG to nanoparticles reduces RES uptake and increases circulation time of the nanoparticles 
in both drug delivery and imaging applications (Jokerst et al., 2011). 
 
4.1. Synthesis and characterization of gold nanoparticles 
The advantages of using nanoparticles as delivery vehicles include their high stability, high 
drug loading capacity, the feasibility of incorporating both hydrophobic and hydrophilic 
substances as well as the feasibility of using various administration routes to deliver the 
nanoparticles (Gelperina et al., 2005).  
Gold compounds have been used in medicine throughout history. The advantages of using 
AuNPs in Nanotechnology include the easy, simple, cheap, safe and reliable synthesis 
methods (Patra et al., 2010). 
According to Abdelhain and colleagues the most widely used method for characterizing 
optical properties and electronic structure of nanoparticles is by UV–visible absorption 
spectroscopy where the absorption bands are related to the width of the nanoparticles 
(Abdelhain et al., 2012). UV–vis data were provided for both the AuNP–E and AuNP–P–E as 
represented in Figure 3.5 (a) and Figure 3.5 (b), respectively. 
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AuNP–E and AuNP–P–E were also characterized by Transmission Electron Microscopy 
(TEM). Figure 3.6 (a) shows the TEM image of the AuNP–E and Figure 3.6 (b) shows the 
TEM image of AuNP–P–E. The TEM images show that the conjugated nanoparticles had a 
spherical shape and were uniformly distributed. The initial size of the nanoparticles were 14 
nm. Theoretically, little to no change in nanoparticle size should be observed upon 
conjugation. It must be noted that no experiments were conducted to determine the size of the 
nanoparticles post conjugation.  
 
4.2. The expression levels of XIAP in human cancer cell lines 
In this study the expression levels of XIAP was investigated in 6 human cancer cell lines 
(A5495, H157, HepG2, HeLa, HT29 and MCF7). Tamm and colleagues investigated the 
expression of the IAP family of anti–apoptotic genes (cIAP1, cIAP2 and XIAP) within the 
NCI panel of 60 human tumour cell lines. They compared expression of cIAP1, cIAP2 and 
XIAP at mRNA and protein levels. It was observed that mRNA levels of cIAP1, cIAP2 and 
XIAP did not correlate to the respective protein levels. It was also observed that cIAP1 and 
XIAP were expressed in most of the human cancer cell lines analysed (Tamm et al., 2000). 
Using Western blot analysis, Tamm and colleagues observed higher XIAP levels in renal 
cancer and melanoma cell lines, whereas low XIAP levels typically present in the Central 
Nervous Systems (CNS) tumour cell lines. 
From Figure 3.2 and Figure 3.3 it can be concluded that the expression levels of XIAP were 
significantly higher in H157 and MCF7 cells when compared to A5495, HepG2, HeLa and 
HT29 cells. It was observed that XIAP expression for HT29 resulted in shared consensus 
between the data generated in this study and that reported by Tamm and colleagues. However 
it was observed that XIAP expression in MCF7 cells was not in agreement with the findings 
of Tamm and colleagues which reported low expression of XIAP in MCF7 cells, whereas this 
study found high expression of XIAP in these cells. Based on the results in Figure 3.2 MCF7 
and HepG2 cells were used as models of cell lines that expressed high and low levels of 
XIAP, respectively. 
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4.3. The cytotoxic effects of AuNP–E and AuNP–P–E  
The effects of ceramide, embelin, AuNP, AuNP–E and AuNP–P–E were investigated in 
MCF7 breast and HepG2 liver cancer cells. Figure 3.7 and Figure 3.8 shows the 
morphological effects, of the various treatments, for HepG2 and MCF7 cancer cells, 
respectively. Apoptosis was investigated for both HepG2 and MCF7 cancer cells (Figure 
3.9). Treatments with embelin, AuNP, AuNP–E and AuNP–P–E did not have any effect on 
the cell morphology as the morphology of these cells resembled that of the untreated cells. 
This suggests that embelin, AuNP, AuNP–E and AuNP–P–E did not have any observable 
effect on MCF7 and HepG2 cell morphology at the concentrations tested. According to the 
statistical analysis, the data obtained for AuNP–E and AuNP–P–E are similar to the data 
obtained for the untreated cells. This was observed for both the MCF7 and HepG2 cells. 
Therefore, the data obtained were statistically significant. 
Ceramide induced morphological changes (cell shrinkage, cell rounding and cell 
detachment), which were indicative of apoptosis. Co–treatment of cells with ceramide and 
embelin, ceramide and AuNP–E, or ceramide AuNP–P–E enhanced the effect of ceramide on 
the morphology of the cells since an increased number of cells were affected by these co–
treatments. This is more evident in HepG2 cells co–treated with ceramide and AuNP–E 
which show that a high number of cells detached from the surface of the culture plate. 
Stock solutions of embelin and ceramide were prepared in DMSO. Even though a vehicle 
control was not included in the cell culture experiments, the concentration of DMSO post 
treatment was below 0.15 % (v/v). This concentration was proved to be non–toxic to the cells 
by Dr. Meyer (data not shown). Therefore, it may be concluded that the morphological 
changes observed  in the treatments consisting of ceramide was as a result of the effects of 
ceramide. 
Based on Figure 3.9 approximately 60% of MCF7 and HepG2 cells treated with 50 µM 
ceramide stained positive for apoptosis. Treatments with embelin, AuNP, and AuNP–E did 
not induce apoptosis in HepG2 cells. However, MCF7 cells treated with AuNP were more 
susceptible to the effects of AuNP, with approximately 30% of the cells being positive for 
apoptosis. MCF7 and HepG2 cells co–treated with ceramide and AuNP–P–E did not enhance 
the effect of ceramide on the cells. However, co–treatment with ceramide and AuNP–E 
enhanced the effect of ceramide in HepG2 cells. The percentage apoptotic cells increased 
from 50% (single ceramide treatment) to 90% (co–treatment with ceramide and AuNP–E). 
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This increased cell death in response to co–treatment with ceramide and AuNP–E was not 
observed in MCF7 cells. 
 
4.4. Evaluating cellular uptake of AuNPs 
ICP–OES was also used to determine the percentage of gold present in the cells treated with 
AuNP–E and AuNP–P–E. Based on Figure 3.10 (a) the concentration of gold in both MCF7 
breast and HepG2 liver cancer cells were significantly higher in cells treated with AuNP–P–E 
(~0.25 µg/ml) compared to cells treated with AuNP–E (~0.01 µg/ml). This demonstrates that 
gold nanoparticles conjugated with the cancer targeting peptide is taken up more efficiently 
by the cells compared to gold nanoparticles without the cancer targeting peptide. MCF7 cells 
have taken up more gold than HepG2 cells, which may be due to the fact that these cells 
express higher levels of the targeting molecule for the peptide.  
Based on the ICP–OES results, AuNP–P–E appear to be more effective in delivering embelin 
to cancer cells. The expectation is that AuNP–P–E should therefore also be more cytotoxic 
than AuNP–E nanoparticles. However, the results generated using the APOPercentage™ 
assay (Figure 3.9) is not in agreement with this. The possibility exists that the nanoparticles 
could have been taken up by the vesicles. Therefore, they were not accessible to the 
mitochondria as observed in Figure 3.11. Alternatively, since AuNP–P–E nanoparticles are 
biconjugated with the cancer targeting peptide and embelin, it is possible that these particles 
do not carry high amounts of embelin into the cells or that the embelin is not functional 
(which could be as a consequence of bioconjugation) and is therefore not able to inhibit 
XIAP. Even though AuNP–E nanoparticles are not taken up by the readily as AuNP–P–E 
nanoparticles, these nanoparticles carry more embelin into the cells (since these particles are 
only conjugated with embelin and not the peptide as well) and are therefore more effective in 
blocking the effects of XIAP.  
Co–treatment with ceramide and AuNP–E induced higher levels of apoptosis in HepG2 cells 
compared to cells co–treated with ceramide and AuNP–P–E, while apoptosis induced by co–
treatment with ceramide and AuNP–E was lower in MCF7 than HepG2 cells. Co–treatment 
with ceramide and AuNP–P–E was more effective in HepG2 cells compared to MCF7 cells. 
This can possibly be ascribed to the fact that HepG2 cells express low levels of XIAP. 
Consequently, embelin will have a bigger effect on these cells, compared to MCF7 cells, 
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which express high levels of this protein. In other words, the amount of embelin delivered to 
the cells was sufficient to block XIAP in HepG2 cells, but not in MCF7 cells. 
Cells treated with AuNP or co–treated with ceramide and AuNP–P–E were evaluated by 
TEM to verify the presence of AuNP within cells. AuNPs were observed in clumps in the 
perinuclear space within the membrane bound organelles in both the HepG2 and MCF7 
cancer cells treated with AuNP’s (Figure 3.11). However, AuNPs were absent in HepG2 and 
MCF7 cancer cells (Figure 3.11) co–treated with ceramide and AuNP–P–E. Structures, which 
are likely to be lipid rafts, were present in the cytoplasm of these cells. These lipid rafts are 
absent in the untreated control cells and cells treated with AuNP. It is therefore likely that 
these lipid rafts are the consequence of ceramide treatment. Sphingolipids, the family of 
membrane lipids, have important structural roles in regulating fluidity and sub–domain 
structures of the lipid bilayer (Ogretmen and Hannun, 2004). With sphingomyelin as the main 
lipid plasma membrane of mammalian cells, it is a given that ceramide is a major source 
resulting from sphingomyelin hydrolysis (Hannun, 1996; Herr and Debatin, 2001). Therefore, 
it was concluded that the structures present in the ceramide treated cells were likely to be 
lipid rafts. 
 
4.5. Expression and purification of recombinant XIAP protein 
Based on the results obtained for ICP–OES and the APOPercentage™ assay (as discussed in 
Section 4.5), the nanoparticles biconjugated with embelin and the targeting peptide may not 
be able to bind to XIAP. To investigate the interaction between XIAP and embelin, XIAP and 
AuNP–E and XIAP and AuNP–P–E, recombinant XIAP protein was required. The human 
XIAP gene cloned was into the pET28a protein expression vector to produce a Histidine–
tagged XIAP fusion protein which may be used to study the interaction between XIAP and 
embelin, XIAP and AuNP–E, and XIAP and AuNP–P–E.  
The XIAP gene was cloned from the MCF7 human breast cancer cell line. This was achieved 
by isolating total RNA (Figure 3.12) for the generation of cDNA (Figure 3.13). XIAP gene 
specific primers were used to PCR amplify the cDNA which resulted in a DNA fragment 
with a size of ~1500 bp (Figure 3.12). This is likely to be XIAP as XIAPs expected size is 
1494 bp. The PCR amplified product was ligated into the pGEM–T Easy PCR cloning vector 
and positive clones were identified by colony PCR (Figure 3.14). The colony PCR screen 
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shows that 9 (colony number 1, 3, 5, 7 and 10) of the 10 colonies were positive for the XIAP 
gene. Colony number 8 failed to produce the ~1500 bp amplicon and therefore does not 
contain the XIAP gene. 
DNA sequence analysis (Figure 3.15) of colony 3 showed that this clone was 99% identical 
to the XIAP gene sequence (NM_001167.2) used to design the primers. Three base changes 
C to T at position 101, A to G at position 826, and A to G at position 932 was detected. These 
base changes are unlikely to be artefacts of the sequence reactions since the clone was 
sequenced in the forward and reverse direction with the M13 forward and M13 reverse 
primers and both sequences produced the same base changes. These base changes could also 
be the result of PCR artefacts caused by the incorporation of the incorrect bases during PCR 
amplification (caused by high dNTP concentrations and Taq polymerase errors) of XIAP 
gene from the MCF7 cDNA library. However, since the same base changes were identified in 
clone number 10 it can be concluded that these base changes are not the result of PCR 
artefacts, but are more likely to be base changes or mutations in the MCF7 cells. 
The translation of the DNA sequence for colony 3 into protein sequence shows two mutations 
in the protein sequence at positions 34 and 176 (Figure 3.16). At position 34 the valine 
residue was changed to alanine, while the valine residue in position 176 was changed to 
isoleucine. Since valine, alanine and isoleucine are all non–polar, aliphatic residues (Garrett 
and Grisham, 2005) these mutations are not expected to have major effects on the XIAP 
protein. The third mutation within the DNA sequence was not detected in the protein 
sequence. It can therefore be concluded that the third mutation may be a silent mutation as it 
does not cause a change in the amino acid. 
Restriction digestion of the pGEM–XIAP plasmid DNA, with XhoI and NdeI, released a 
DNA fragment of ~1500 bp (Figure 3.16). As the fragment had the expected size for XIAP, it 
was sub–cloned into the pET28a expression vector previously digested with XhoI and NdeI 
(Figure 3.18). Positive clones were identified by PCR amplification (Figure 3.19). All 8 
colonies that were screened produced a ~1500 bp fragment, suggesting that they all contained 
the XIAP gene. Four of these clones (Clone number 1, 2, 3 and 4) were selected for a small–
scale protein expression analysis. 
Figure 3.20 shows the results for the protein expression screen on the above mentioned 
clones. The presence of a prominent 47 kDa protein can be seen in the protein samples. This 
is the expected size for the XIAP–Histidine tagged protein. However, there is no clear 
 
 
 
 
92 
 
evidence that this protein is induced in the presence of IPTG, since the intensity of the 47 
kDa band is the same in the uninduced and induced samples. Western blot analysis was used 
to confirm the presence of XIAP in these samples (data not shown). 
A large scale expression (Figure 3.21) of the XIAP–Histidine tagged protein was attempted 
using the Novagen Ni–NTA His–Bind® Resin. Figure 3.21 clearly shows the presence of a 
47 kDa protein in the lysate and flow through. The intensity of the 47 kDa protein is the same 
in the lysate and flow through suggesting that the protein did not bind the resin efficiently. 
This is confirmed by the fact that a 47 kDa protein was also collected in the first wash. Very 
low amounts of a 47 kDa protein was eluted in Eluate 1. In an attempt to optimize the binding 
efficiency different concentrations of imidazole was used. Unfortunately, this proved to be an 
unsuccessful task (data not shown). As purification of the XIAP–Histidine tagged protein was 
unsuccessful using the Ni–NTA His–Bind® Resin as well as different imidazole 
concentrations, purification was attempted using the HIS–Select® Nickel Affinity Gel 
(Sigma–Aldrich). The HIS–Select® resulted in unsuccessful purification (data not shown) as 
insufficient protein was eluted.  
Hexa–histidine tags and glutathione S–transferase (GST) tags are commonly used for the 
purification of recombinant proteins (Scheich et al., 2003), but these tags are not equally 
effective in purifying recombinant proteins.  
Braun and colleagues compared the efficiency of 4 affinity tags (namely GST, Maltose 
Binding Protein (MBP), Hexa–histidine and Calmodulin Binding Protein (CBP)) for 
application in the purification of recombinant proteins under denaturing and non–denaturing 
conditions. The purification of 36 different proteins was evaluated using all 4 affinity tags. 
Under non–denaturing conditions only 4 of the 32 proteins purified by the 6×His–tag were 
detected via Coomassie stained SDS PAGE and 15 of the 32 proteins were detected by 
Western blot analysis. Of the 4 proteins, only MAX and p16
INK4a
 were reasonably pure (i.e. 
70%). All His–tagged proteins were lost in the flow through and/or could not be eluted from 
the matrix. This was true for both Ni
2+
 and Co
2+
 matrices and with a broad range of imidazole 
concentrations ranging between 200 and 500 mM or 5 mM EDTA used for the elution in the 
presence of 500 mM NaCl. Possible reasons for the low success rate of His–tagged protein 
purification could be due to protein loss in the flow through and/or the protein not efficiently 
eluted from the resin. Under non–denaturing conditions for the GST–tagged proteins: 26 
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proteins of the 32 were purified with a yield of at least 300 ng protein per ml of culture, while 
22 of these proteins produced a yield of > 1 µg protein per ml of culture (Braun et al., 2002).  
The Braun study demonstrated that GST is more suitable for the purification of recombinant 
proteins. Consequently, a DNA construct (pGEX–4T–2–XIAP) that can be used to express 
recombinant GST–XIAP fusion protein was purchased from Addgene. 
An expression screen was performed on 4 clones to identify clones that express the GST–
XIAP protein. The expected size of GST–XIAP is 76 kDa. Figure 3.21 shows the expression 
of a ~75 kDa in the induced protein samples. Although this protein was also present in the 
uninduced protein samples, it is clear that the intensity of the 76 kDa protein was higher in 
the induced samples. Clone number 3 was used for large scale expression and purification of 
the GST–XIAP recombinant protein. 
Figure 3.23 shows purification of the GST–XIAP recombinant protein using Novagen’s 
BugBuster® GST–Bind Purification Kit (Merck). A protein band corresponding to the 
approximate size of 75 kDa was present in the Pellet (insoluble protein), Lysate (soluble 
protein), Flow through, the first Wash as well as Eluates 1, 2 and 3. No GST–XIAP was 
present in the Second wash. The fact that the 75 kDa protein band is so intense in the Pellet 
suggests that a large amount of the protein is expressed in inclusion bodies.  
Inclusion bodies produced in E. coli are composed of densely packed denatured protein 
molecules. Inclusion bodies are formed from partially folded protein intermediates and are 
composed of aggregates of mostly single polypeptide. This assists in isolating and purifying 
protein aggregates of mostly single polypeptide types. This helps in isolating and purifying 
protein aggregates to homogeneity prior to solubilisation and refolding. Proteins occurring in 
the form of inclusion bodies possess native–like secondary structures (Singh and Panda, 
2005).  
Although the Lysate (soluble protein) contained the 75 kDa protein band, a large quantity of 
the protein was still present in the Pellet. This protein is also present in the Flow through, 
suggesting that the protein do not bind to the resin efficiently. Nonetheless, the amount of 
protein present in Eluates 1, 2 and 3 are significantly more that the His–XIAP protein purified 
using the Ni–NTA His Bind® Resin.  
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4.6. Protein–Protein Interactions 
Technologies that can be used to analyse the interaction between biomolecules or 
biomolecules and drugs are very important for pharmaceutical drug development as well as 
the study of biology (Wienken et al., 2010). Isothermal Titration Calorimetry (ITC) and 
Surface Plasmon Resonance (SPR) are two technologies that can be used to perform these 
studies.  
4.6.1. Isothermal Titration Calorimetry 
ITC is a sensitive technique capable of measuring heat absorption or heat release as a result 
of the interaction between the two reacting species (Toshima et al., 2005; Olsen 2006; 
Bouchemal, 2008). ITC has been applied to determine stability constants, stoichiometry and 
interaction enthalpies. In certain experiments ITC had been used to determine entropies, 
Gibbs free energies as well as heat capacity changes (Bouchemal, 2008). 
In an ITC experiment, it is necessary to have the addition of reactant to a sample solution that 
contains other reactants required for that reaction. After addition of the reactants, heat may 
either be absorbed or released. Heat reactions are monitored by ITC as peaks of power versus 
time per injection. Development of ITC data analysis methods is one of the most important 
researches in the field of thermodynamics for protein ligand interaction studies (Saboury, 
2006). 
ITC is becoming a reliable tool for the characterization of intermolecular interactions. Both 
high and low affinity interactions may be quickly and accurately characterized by ITC. In this 
technique reactive materials may be studied not only in solution but also as particulate 
suspensions since turbidity or sample colour has no influence the measurements. The 
thermodynamic parameters of the interactions can be measured without immobilization, 
modification or labelling of the binding partners and there is no molecular weight restrictions 
with this technology (Bouchemal, 2008). 
4.6.2. Applications of ITC to study for Protein–Nanoparticle Interactions 
ITC may be used to investigate the thermodynamics of protein–nanoparticle interactions 
(Lynch and Dawson, 2008). The protein of interest can be injected into the sample cell 
containing a solution of the nanoparticles onto which the ligand for the protein was 
conjugated.  
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Information on the binding affinities and stoichiometries for different combinations of 
proteins and nanoparticles are regarded as highly relevant in the field of nanotechnology. It 
must be considered that nanoparticles used to deliver drugs will encounter countless 
biomolecules (including proteins) in bodily fluids and intracellular environments that are not 
necessarily the target of the nanoparticle. Knowledge of the critical parameters that determine 
the interaction of nanoparticles with the intended target or ligand is therefore important to 
assess their biological effects. Rates of association and dissociation are likely to have 
considerable differences depending on the protein, the ligand and the type of particle. The 
association rate constants of some complexes approach the limit of diffusion–control whereas 
conformational changes upon binding may also slow the process by magnitude orders.  
 
4.7. Investigating the binding between the recombinant GST–XIAP and embelin 
XIAP is a known target of embelin. However, the conjugation of embelin AuNPs could have 
diminished the binding efficiency of embelin for XIAP. As discussed in Section 4.5, the 
failure of AuNP–P–E to enhance ceramide–induced apoptosis (even though it is taken up by 
cells more effectively than AuNP–E) could be due to the fact that embelin conjugated to 
AuNP–P–E is not able to bind XIAP. Attempts were made to study the interaction between 
the AuNP–P–E and XIAP, using the MicroCal™ iTC200 System. As a positive control, a 
binding experiment was carried out between calcium and EDTA. 
A curve was fitted to the data as shown in Figure 3.23 (b). This normalized data is 
represented as kcal/mol of EDTA versus the molar ratio. From the curve the numbers of 
peaks, representing the EDTA injections, were calculated to be 0.894 ± 0.00513, the binding 
constant at 2.33 x 10
6
 M
-1
 ± 9.90 x 105, heat change at -3774 cal/mole ± 45.37 and entropy 
change at 16.5 cal/mole/deg. 
However, the ITC result for GST–XIAP and embelin failed to show that there is interaction 
between the drug and the protein. A possible reason for the failed experiment could be the 
low concentration of the recombinant GST–XIAP protein. The following equation was used 
to determine the desired concentration of the recombinant GST–XIAP protein: 
M = 10 × Kd  
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where M represents the concentration required for GST–XIAP protein and Kd the dissociation 
constant between XIAP and embelin. 
For the experiment to be carried out successfully, the required concentration of the 
recombinant GST–XIAP protein is 4 µM. The concentration of GST–XIAP was 6 nM, which 
is approximately 7 fold less than the concentration required to study the interaction between 
embelin and GST–XIAP. However, because the quantities of recombinant GST–XIAP 
protein purified in this study were so low, it was not possible to carry out the experiment. 
The presence of the GST tag could also have interfered with the experimental procedure. It 
may be considered to perform an additional experiment where the interaction between 
embelin and XIAP is investigated after the removal of the GST tag from the fusion protein. 
Alternatively, SPR can be used to study the interaction between XIAP and embelin. SPR is 
an optical phenomenon which can be used for detecting and measuring the concentration of 
the counterpart, or for characterising the kinetics and affinity of binding, by monitoring the 
change in optical properties during binding and dissociation (Lofas and Johnson, 1990). An 
example of SPR is the Biocore T200 (GE Healthcare). It uses the principle of SPR to study 
protein–protein and protein–drug interactions. The advantages of SPR over ITC is that it 
requires less of the potential ligands and seeing that the purification of GST–XIAP is 
problematic SPR may be a better alternative. 
 
4.8. Conclusion 
The objective of this study was to develop AuNP’s that can be used to target the delivery of 
embelin to cancer cells and enhance the pro–apoptotic effects of ceramide. AuNP’s were 
synthesized and conjugated with embelin and the cancer targeting peptide with the following 
amino acid sequence: LTVSPWY. This study showed that cancer cells very efficiently take 
up AuNP conjugated with this peptide. AuNP conjugated with embelin significantly 
enhanced the pro–apoptotic effects of ceramide and can therefore be used to kill cancer cells 
more effectively. However, AuNP biconjugated with embelin and the targeting peptide failed 
to enhance the pro–apoptotic effects of ceramide. It is likely that biconjugation with the 
targeting peptide lowered the embelin loading on the particles and consequently these 
particles are not able to deliver embelin efficiently to the cells.  
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Even though this study requires further optimization, it successfully demonstrated that AuNP 
conjugated with embelin could be used to enhance the effects of anti–cancer drugs.  
 
4.9. Future Directions 
The present study has limitations that need to be addressed. The investigation into the 
interaction between XIAP and embelin, XIAP and AuNP–E and XIAP and AuNP–P–E was 
not completed in this study. The limiting factor was the amount of interaction of recombinant 
XIAP. Therefore the purification of recombinant GST–XIAP will need to be optimized. The 
removal of the GST tag from the GST–XIAP fusion protein can possibly also resolve the 
problems experienced with ITC. Alternatively, instead of using ITC, these interactions may 
also be studied by SPR. 
Compared to AuNP–E, AuNP–P–E was not very effective in promoting ceramide induced 
apoptosis in the cancer cells. It is likely the molar ratio’s of AuNP:targeting peptide:embelin 
used in the synthesis of the nanoparticle resulted in the particle carrying more of the peptide 
and less of the embelin. It would therefore be adviseable to optimise the molar ratio’s of the 
AuNP, targeting peptide and embelin in order to produce a nanoparticle that can target the 
cancer cells efficiently, but still carry sufficient quantities of embelin to the cells. 
Finally, the treatments with AuNP–P–E as well as AuNP–P–E and ceramide should be tested 
on other cancer cell lines as well. Also, apoptosis induction should also be investigated using 
anti–cancer drugs. 
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